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  Cancer is a known condition characterized by uncontrolled cell growth and 
spread of abnormal cells. Head and neck is a predilected site for a large number of 
cancers among which the squamous cell carcinomas predominate in the oral 
cavity. Patients with cancer in the head and neck can be treated with surgery, 
chemotherapy, radiotherapy, or a combination of both treatment modalities32. 
 
  Oral mucositis is a common side effect of cancer therapies, particularly 
radiation therapy for head and neck and various forms of chemotherapy. It 
commonly results in severe pain that can compromise the duration and success of 
cancer management31.  
 
  Oral mucositis is defined as oral mucosal change secondary to cancer 
therapy. It manifests first by thinning of oral tissues leading to erythema. As these 
tissues continue to thin, ulceration eventually occurs. Inhibition of cell growth and 
maturation by radiation and chemotherapy disrupts the primary mucosal barrier of 
the mouth and throat, creating a pathway for the establishment of oro-pharyngeal 
infection by resident oral microflora. Consequences of this include oral mucositis 
and gingivitis, oral candiasis, xerostomia, trismus, dental caries, 
osteoradionecrosis, cellulitis, and viral mucosal eruptions. These oral 
complications may cause significant patient discomfort, poor nutrition, delay in 
administration or dosage limitations in antineoplastic treatments, increased 
hospitalization stays and costs, and in some patients, life-threatening septicemia14. 
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  In addition, severe mucositis may require temporary or permanent 
cessation of radiation or chemotherapy before completion of the planned treatment 
regime. This is of a marked concern, as there is strong clinical and radio-biologic 
evidence that protraction of overall treatment time has adverse influences on the 
curability of certain human tumors, particularly squamous cell carcinoma of the 
head and neck region4. 
 
  For prophylaxis of oral mucositis, various agents are used in order to 
reduce the incidence and severity of mucositis25. Sodium bicarbonate reduces the 
acidity of the oral fluids immediately. It dilutes accumulating mucus and 
discourages yeast colonization. Chlorhexidine gluconate is an antimicrobial agent 
that appears to be effective in controlling early periodontal infections. Hydrogen 
peroxide, once recommended as an oral rinse to aid in the management of 
adhesive mucus and the oxygenation of the oral tissues, has recently come into 
dispute because of its possible carcinogenic and its ant fibroblast healing – 
delaying action5.   
 
 Anecdotal reports suggested that the ‘magic’ mouthwash which consisted 
of “mixtures” aimed at producing analgesia or anesthesia and coating the inflamed 
and painful oral mucosa. There is not much evidence existing to support the 
efficacy of this mixture in the treatment of mucositis. The 3 most common 
ingredients in these mixtures are viscous lidocaine solution, diphenhydramine 
hydrochloride and aluminum hydroxide suspension. However, because the use of 
these agents is common in clinical practice, this combination could be a material 
of choice for treating mucositis9. 
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  An ideal oral rinse for patients with head and neck malignancies should 
reduce the oral micro flora, promote re-epithelization of soft tissue lesions, 
normalize the pH of oral fluids, have an acceptable taste, and be nontoxic5. A 
preliminary study reported that alcohol-free mouthrinses cause less patient pain 
than those containing alcohol. It is accepted that tobacco and alcohol are two risk 
factors for oropharyngeal cancer; however, the association between cancer and the 
use of alcohol – containing mouthrinses is still being evaluated4.  
 
  Alcohol is used in mouthrinses as a dissolvent of other ingredients and as 
an antiseptic agent. Its presence on mouthrinses is detrimental to patients with 
mucositis, who are immunocompromised, or are sensitive to the ingredient. Its use 
is also contraindicated in patients undergoing radiations therapy for head and neck 
cancers, which is known to cause xerostomia, ulcerating gingivitis, and tissue 
damage. These conditions may be exacerbated by alcohol. Ethanol can also 
contribute to surface softening and can increase wear of dental caries and 
composite materials4. 
 
  The development and use of alcohol free mouthrinses are relatively new. 
Certain studies have shown their efficacy and lack of side effects, but there is no 
clear confirmation6. The present study was done to find the effect of three alcohol 
free mouthwashes on radiation and combination therapy induced oral mucositis in 
patients with head and neck malignancies. 
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Treatment of head and neck cancer represents a significant challenge to the 
oncologist because of the poor prognosis, associated medical problems and 
adverse effects of treatment on patient function and appearance17. Patients often 
are treated in a multidisciplinary clinic. Treatment usually consists of a 
combination of surgery, chemotherapy and radiation therapy. The aim of the 
treatment is to cure the patient while maintaining as much function of the involved 
organs as possible. If surgery and radiation therapy offer similar cure rates, the 
cosmetic and functional sequelae of the different treatment modalities influence 
the approach chosen. If the cancer is advanced and cure is not possible, the 
treatment goal is palliation17. 
 
Radiotherapy is done by using ionizing radiation in the treatment of 
cancer6. The ionizing radiation produce their tumoricidal effects by virtue of their 
direct ionizing effect on the DNA of the cell as well as their indirect effect on the 
cell membrane, which is mediated by free radicals generated by the hydrolysis of 
water in the tissues6. Although both tumor tissue and normal tissue suffer from 
radiation induced damage, the lack of repair capacity in the undifferentiated tumor 
tissue renders the radiation damage permanent. The presence of repair 
mechanisms in the normal tissue enables them to get away with minimal radiation 
induced damage provided the radiation is given in small doses separated by a 
definite time interval6. When the dose of radiation exceeds the specific radiation 
tolerance dose of normal tissues it leads to side effects which are invariably 
permanent. The effect and benefits of radiation are not immeidate17. Typically, 
more aggressive tumors, whose cells divide rapidly, respond more quickly to 
radiation. Radiation therapy is painless and does not make the patient radioactive. 
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Radiotherapy consists of two broad treatment modalities namely 
Teletherapy and Brachytherapy3. In Teletherapy the patient is placed at a distance 
of 80-100 cm from the radiation generating equipment which contains either a 
radioactive source (co-60 gamma radiation produced by a Telecobalt machine) or 
generates high energy X rays and electrons (as in the Linear accelerator) 3. The 
advantage of Teletherapy is that the divergence of the radiation beam resulting 
from the large treatment distance enables treatment of a large tumor bearing area 
(eg Buccal mucosa and neck) to a uniform dose. The disadvantage of Teletherapy 
is that some amount of normal tissue irradiation and hence normal tissue side 
effects are unavoidable. The essence of treatment planning lies in minimizing the 
dose to normal tissue while ensuring that the tumor tissue is delivered the 
tumoricidal dose3. Modern forms of Teletherapy such as 3D Conformal 
Radiotherapy and Intensity Modulated Radiotherapy as well as advances in 
imaging such as MRI and PET scan have played an important role in radiation 
dose escalation to tumor tissue without exceeding normal tissue tolerance. 
 
In Brachytherapy the radioactive source is placed in contact with the tumor 
bearing tissue. The small size of the radioactive source used, coupled with the 
principle of inverse square law, which states that the radiation intensity is 
inversely proportional to the square of the distance from the radiation source: 
results in the radiation being concentrated on the tumor   with rapid dose fall off 
and sparing  of normal tissue. The advantage of Brachytherapy is that it delivers 
high conformal dose of radiation to the tumor with maximal normal tissue sparing. 
The disadvantage of Brachytherapy lies in that it can be used as a primary 
radiation modality only in early cancers as it is effective only in small tumor sizes. 
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In advanced malignancies the tumor is first shrunk with Teletherapy and wherever 
feasible Brachytherapy is added in the second phase of radiation as a boost to the 
tumor bed to improve the local control21. 
 
Radiation therapy is important in the cure of the patient with head and 
neck cancer for several reasons. First, most head and neck cancers are 
radiosensitive. Carcinomas limited to the mucosa, exophytic and well – 
oxygenated tumors have a high cure rate with radiation17. Radiotherapy alone is 
used as a curative modality in stage I and II of head and neck cancers as the cure 
rates are equivalent in comparison with surgery and in addition the anatomy and 
physiology are preserved6. In stage III and IV cancers Radiotherapy is used as an 
adjuvant (Post – Op / Pre – OP) to surgery as bone and muscle involvement alters 
the responsiveness of the tumor and decreases radio curability. However if surgery 
is not feasible then alternatively patients suffering from locally advanced head and 
neck cancers with good general condition are subjected to chemo – radiation 
treatment. Patients suffering from systemic head and neck cancers are palliated 
mainly with radiotherapy6. 
 
As every treatment has its side effects, so does radiotherapy. The most 
important acute effect is mucositis which is particularly problematic and is a real 
issue for patients, potentially compromising nutrition and having a negative 
impact on cure rates as well as quality of life17.  Added to these are the potential 
problems associated with the late radiotherapy related side effects, such as 
xerostomia, tooth decay, soft tissue fibrosis and, rarely, osteonecrosis of mandible. 
However in spite of the side effects, Radiotherapy shall remain an inseparable 
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component of head and neck cancer therapy particularly in developing   countries 
where the majority of patients present with advanced cancer.  
 
Radiotherapy – induced mucositis decreases the quality of life by 
impairing eating, swallowing, and talking and by disturbing sleep. Mucositis may 
also predispose to local and systemic infections and may cause interruption of 
radiotherapy course. Years of research work have concentrated to find the 
pathogenesis, associated morbidity factors and prevention of oral mucositis 
induced by radiation therapy in patients with head and neck malignancies. An 
attempt has been made to cite a few of them below. 
 
Pathogenesis of mucositis  
 Dobbs et al8 in 1989 suggested that the majority of new cases of invasive 
head and neck cancer will need radiotherapy as a primary treatment, as an adjunct 
to surgery, in combination with chemotherapy, or as palliation The radiation dose 
needed for the treatment of cancer is based on location and type of malignancy, 
and whether or not radiotherapy will be used solely or in combination with other 
modalities. Most patients with head and neck carcinomas, treated with a curative 
intent, receive a dose between 50 and 70 Gray (Gy). This dose is usually given 
over a five to seven – week period, once a day, five days a week, 2 Gy per 
fraction. The most important dose limiting factor is the tolerance of the adjacent 
normal tissues. Depending on stage and location of the primary tumor and 
affected lymph nodes; the oral cavity, salivary glands, and jaws of most head and 
neck cancer patients may be located in the radiation portals. Even with the most 
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optimal radio therapeutic schedule, unwanted radiation induced changes will 
occur in these tissues. 
 
 Dorr and Kummermehr in 19903 using a mouse model explained the 
mucosal changes following radiation as follows. The lack of formation of new 
basal cells caused by radiotherapy leads to a gradual, linear decrease in cell 
numbers. If the cellularity of the mucosa drops below 70% of the normal level, the 
cell production rate from the surviving cells increases dramatically (a possible 
cause for the whitish aspect of oral mucosa). As radiotherapy continues, a steady 
state between mucosal cell killing and mucosal cell regeneration may occur and 
favour an acute reaction in the form of a prominent erythema. Around the third 
week of radiotherapy, more severe symptoms of mucositis, such as the formation 
of pseudo membranes and ulceration, may appear. Various signs of mucositis may 
emerge during radiotherapy. The first clinical signs of mucositis occur at the end 
of the first week of a conventional seven – week radiation protocol (daily dose of 
2 Gy, Five times a week). There is no consensus regarding what is the first clinical 
sign of mucositis. Some authors describe a white discoloration of the oral mucosa, 
which is an expression of hyperkeratinization as the first symptom, followed by or 
in combination with erythema.  Others consider erythema to be the first reaction. 
 
Dorr and Kummermehr (1990)3 in their study also explained the 
development of pseudo membranes, when radiotherapy commences, as a cell 
regeneration process that cannot keep up with cell killing. As a result, partial or 
complete epithelial denudation develops, which presents as spotted or confluent 
pseudo membranous mucositis. 
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Maciejewski et al in 199120 and Riesenbeck et al in 199827 suggested 
pseudo membranes to be ulcers covered by fibrinous exudates. Others suggest that 
pseudo membranous mucositis is related to yeast stomatitis or to colonization of 
the oral cavity with Gram negative bacilli. 
 
Sonis 199835 considered mucositis to be a 4 step process consisting of the 
following phases- 
  Phase I: Initial inflammatory / vascular phase: During this phase, exposed 
cells (epithelial, endothelial, and connective tissue cells) in the buccal mucosa 
release free radicals, modified proteins, and pro inflammatory cytokines, including 
interleukin – 1B, prostaglandins, and tumor necrosis factor (TNF). These 
inflammatory mediators cause further damage either directly or indirectly by 
increasing vascular permeability, thereby enhancing cytotoxic drug uptake into the 
oral mucosa. 
  Phase II: Epithelial phase: In this phase, chemotherapy and / or radiation 
retards cell division in the oral mucosal epithelium, leading to reduced epithelial 
turnover and renewal, resulting in epithelial breakdown. This results in erythema 
from increased vascularity and epithelial atrophy 4 to 5 days after the initiation of 
chemotherapy. At this stage, micro trauma from day to day activities such as 
speech, swallowing and mastication leads to ulceration. 
  Phase III: Ulcerative / bacteriological phase (Pseudomembraneous): 
Epithelial breakdown ultimately results in the ulcerative phase, which occurs 
within 1 week of therapy. Loss of epithelia and furious exudation lead to the 
formation of pseudo membranes and ulcers. In this phase, microbial colonization 
of damaged mucosal surfaces by Gram – negative organisms and yeast occurs, 
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and this may be exacerbated by concomitant neutropenia. There are numerous 
reports that demonstrate the importance of ulcerative mucositis as an etiologic 
factor in the development of systemic α - hemolytic streptococcal infections in 
cancer patients. 
  Phase IV: Healing Phase: The duration of this phase usually lasts from 12 
to 16 days, and mainly depends on factors such as epithelial proliferation rate, 
hematopoietic recovery, reestablishment of the local microbial flora, and absence 
of factors interfering with wound healing viz infection and mechanical irritation. 
Healing eventually occurs from the surviving mucosal steam cells. Similar 
changes have been observed in humans, in whom the mucositis is characterized by 
loss of epithelial cells, absence of vascular damage, and an inflammatory reaction 
at the epithelial – connective tissue interface.  
 
  Denham et al7, in 1999 suggested that the severity of mucositis varies 
considerably between patients and may relate to the fractionation schedule 
applied. Accelerated fractionation results in a more rapid onset of mucositis. 
Furthermore, the mucosa of the oral cavity does not react in the same manner at 
all locations. Mucositis is most severe in the soft palate, followed, in order, by the 
mucosa of the hypo pharynx, floor of the mouth, cheek, base of the tongue, lips, 
and dorsum of the tongue. Patients with compromised oral mucous membranes 
secondary to alcoholism and / or excessive smoking exhibit the most severe 
mucosal changes. 
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  Handschel et al18, 1999 suggested that radiation induced oral mucositis is 
characterized by atrophy of squamous epithelial tissue and an inflammatory 
infiltrate concentrated at the basement region. Damage to oral mucosa is strongly 
related to radiation does, fraction size, volume of irradiated tissue, fractionation 
scheme, and type of ionizing irradiation44. Oral side – effects develop early during 
radiotherapy. The acute mucosal response to radiotherapy is a result of mitotic 
death of epithelial cells, since the cell cycle time of the basal keratinocytes is 
about four days. 
 
  Steel et al39 in 2002 suggested that tissues with rapid turnover rates show 
acute reactions to radiotherapy (early effects), while in tissues with slower 
turnover rates, damage may not become evident for months or years after therapy 
(late effects). One of the most important acute effects of radiotherapy on the oral 
mucosa is radiation induced mucositis. Mucositis induced by radiotherapy is 
defined as the reactive inflammation of the oral and oropharyngeal mucous 
membrane during radiotherapy in the head and neck region. Radiotherapy induced 
mucositis is not simply an epithelial process; rather it involves micro vascular 
injury resulting from endothelial – cell apoptosis, increased peripheral blood 
levels of tumor necrosis factor a and interleukin – 6 and genetically induced 
differences in the rates of tissue apoptosis. 
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Role of Infection:  
  Spijkervet et al33 in 1989 suggested that mucositis is basically a tissue 
reaction to the trauma of radiation or chemotherapy. Other factors that may 
contribute to the development of mucositis include the increase in the 
inflammatory mediator, platelet activating factor in saliva of irradiated patients; 
leukocyte adhesion to E selection or endothelial intercellular adhesion molecule – 
1 (ICAM -1) which promotes the radiation induced inflammatory response in 
squamous epithelium; a decrease in the level of salivary epidermal growth factor; 
and an increase in the carriage rate of Gram negative bacilli in the oropharynx 
(among other Enterbacteriaceae, Pseudomonaceae). 
 
  Spijervet et al34 in 1991 suggested that marked increase in oral Gram 
negative enterobacteria and pseudomonas could be shown as a possible 
aggravating factor for development of oral mucositis. Less than 10% of healthy 
individuals exhibit colonization of the oral cavity with these non indigenous Gram 
negative bacilli. This is due to the oropharyngeal colonization defense, which is 
determined by the integrity of the anatomical structures, physiology, motility, 
secretions secretary immunoglobulin A, mucosal cell turnover, and the indigenous 
flora. These factors are impaired by radiotherapy for head and neck cancer and are 
negatively influenced by more generalized factors, such as advanced age, medical 
interventions (e.g., surgery) and underlying disease. Selective elimination of Gram 
negative bacilli was associated with a reduction of pseudo membranes and 
ulceration. These authors postulated that Gram negative bacilli or endotoxin 
released by Gram negative bacilli could pay a major role in the development of 
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the advanced stages of radiation mucositis, while the initial signs are basically 
related to irradiation only. 
 
  Ramirez – Amador et al 26 in 1997 suggested that the most common 
infection in the oral cavity during or shortly after radiotherapy is candidiasis. They 
showed that the prevalence of positive candida cultures increased from 43% at 
baseline to 62% at completion of radiotherapy and to 75% during the follow up 
period. Some authors believe that oral mucositis is aggravated by fungal 
infections. However, treatment of yeast and Gram positive cocci with topical anti 
fungals and disinfectants failed to relieve such complications. Thus, many of the 
oral lesions observed during treatment do not seem to be due to candidiasis or 
streptococcal infection. Finally it should be mentioned that herpes simplex virus 
infection is not a significant contributing factor in irradiation mucositis. This is in 
contrast to the commonly seen herpes simplex virus reactivation following 
chemotherapy and chemo radiotherapy patients. 
 
Evaluation of Mucositis: 
  In routine clinical practice as well in the area of research, proper 
assessment of oral mucosa is of paramount importance before initiating radiation 
therapy to the head and neck regions, as well as chemotherapy. Comparisons of 
the toxicity of treatment regimens as well as evaluation of various modes of 
intervention for mucositis have been hindered by the lack of a universally 
acceptable scoring system for the condition.  
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  More than 15 different mucositis scales are currently used. Some are based 
solely on objective (Ulceration and erythema), or descriptive findings 
(pseudomembrane formation), whereas others depend on symptomatic 
interpretation or analgesic or functional outcomes, and others still are driven by 
nursing management endpoints. Presently, the grading system most commonly 
used to describe oral mucosal toxicity associated with radiation and chemotherapy 
treatment regimens is the WHO Scale, which combines symptoms, function, and 
objective findings to arrive at a score13.  
 
  The presumed complexity of mucositis scoring is reflected by the fact that 
different National Cancer Institute (NCI) Common Toxicity Criteria exist for oral 
mucositis associated with head and neck radiation, chemotherapy, and bone 
marrow transplant conditioning regimens. Establishment of a common, accepted 
scale is critical as a benchmark for both describing regimen toxicities and for 
studies in which mucositis treatment are evaluated.  
 
  A variety of protocols and grading systems have been introduced, but only 
a few of them are standardized and validated. A good scoring system is that which 
will consider all patient related factors viz. the patient’s physical and nutritional 
status combined with a detailed inspection of the oral cavity. Clinical severity of 
mucosal injury will vary from mild, moderate and severe conditions. 
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Various grading systems for scoring the severity of mucositis are as follows 
1. World health organization (WHO) grading of mucositis 
2. National cancer institute toxicity criteria for grading stomatitis 
3. Radiation therapy oncology group (RTOG) oral mucositis grading system 
4. Oral assessment guide (OAG) 
5. Objective scoring system for the site assessment 
World health organization (WHO) grading of mucositis is the universally accepted 
method for assessing the severity of mucositis. 
 
World Health Organization (WHO) grading of mucositis13   
This scoring system is widely used in routine clinical practice and clinical trials 
for the evaluation of mucositis. It is grated from 0 to 4 as follows- 
Grade 0 No symptom. 
Grade 1 Soreness and erythema. 
Grade 2           Erythema, ulcers; can eat solid foods. 
 Grade 3 Ulcers, requires liquid diet only.  
 Grade 4     No possible alimentation. 
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Chemoradiotherapy - dosages and regimens 
  Tanguay Y Seiwert et al (2007) 36 explored the use of chemoradiotherapy 
in head and neck cancer stating that the advent of chemoradiation has significantly 
contributed to the curability of head and neck cancer, including locoregionally 
advanced disease. The article also reviews the available chemoradiotherapy 
standards used for head and neck cancer, which initially focus on single-agent 
cytotoxic-based regimen and later on multiagent-based regimens. The present 
focus is on preserving organ function and reducing toxic effects. The guidance for 
clinicians based on current clinical trial evidence on how to choose appropriate 
treatment platforms is also provided. 
 
  Ryan and Burri (2009) 28 in their review article on chemotherapy and 
radiotherapy for patients with head and neck cancer stated that more than 500,000 
cases were reported to have diagnosed with cancer. Head and neck cancer require 
a multidisciplinary setting to manage. Various combinations for managing such 
patients include surgery, radiotherapy, chemotherapy and more recently the 
biologic therapy. The ultimate aim of treatment included minimizing tumor 
control while maintaining function and quality of life. Most patients with locally 
advanced disease, and multimodality organ conserving therapy were often 
employed for these patients. This article focuses on the rationale and evidence 
supporting the use of concurrent chemotherapy in the management of locally 
advanced head and neck cancers. 
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Radiation induced mucositis and its management 
  Wolfgang J. Kostler et al (2001) 44 in their over view on options for 
prevention and treatment of oral mucositis stated that oral mucositis represents a 
major non-hematologic complication of cytotoxic chemotherapy and radiotherapy 
associated with significant morbidity that may delay the treatment plan itself. The 
article narrates the incidence, pathogenesis and predisposing factors for oral 
mucositis. The prophylactic and therapeutic armamentarium for the treatment of 
oral mucositis which consists of locally and systemically applied 
nonpharmacological measures and pharmacotheraputics are also discussed. 
 
  Trotti et al (2003) 38 in his systematic review to determine the frequency 
of mucositis and associated outcomes in patients receiving radiotherapy for head 
and neck cancer collected the randomized clinical trials of patients with head and 
neck cancer receiving radiation therapy with or without chemotherapy that were 
reported. 33 studies were included which met with the inclusion criteria. 
Mucositis was defined using a variety of scoring systems. It was found that the 
mean incidence was 80% and only 56% patients experienced severe mucositis 
among the patients who were treated with altered fractionation compared with 
34% of conventional radiotherapy. Rates of hospitalization due to mucositis were 
reported only in 3 studies and it was 32% for patients treated with altered 
fractionation and 16% for conventional radiotherapy. 11% of patients had altered 
fractionation regimens interrupted or modified because of mucositis in 5 studies. It 
was concluded that mucositis is a frequent toxicity in patients with head and neck 
cancer and it may lead to hospitalization and treatment interruptions. 
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  Spencer W. Reeding (2005) 31 in his review article on cancer therapy 
related oral mucositis stated that oral mucositis is a common side effect of cancer 
therapies, particularly radiation therapy for head and neck cancer and various 
forms of chemotherapy. It manifests first by thinning of oral tissues leading to 
erythema. As these tissues continue to thin, ulceration eventually occurs. It 
commonly results in severe oral pain that can compromise the duration and 
success of cancer management. The author also reviewed the current concepts on 
the epidemiology, pathophysiology, prevention and treatment of cancer related 
oral mucositis. 
 
Comparing various scoring systems for mucositis 
  Spijkervet et al (1989) 32 defined irradiation mucositis as an 
inflammatory-like process of the oropharyngeal mucosa following therapeutic 
irradiation of patients who have head and neck cancer. Clinically, it is a serious 
side effect because severe mucositis can cause generalized problems (weight loss, 
nasogastric tube feedings) and interferes with the well-being of the patient 
seriously. Grading mucositis is important for the evaluation of preventive and 
therapeutic measures. The object of this study was to develop a scoring method 
based on local mucositis signs only. Four clinical local signs of mucositis were 
used in this score: white discoloration, erythema, pseudomembranes and 
ulceration. Mucositis of the oral cavity was calculated during conventional 
irradiation protocol for 8 distinguishable areas using the 4 signs and their extent. 
A prospective evaluation of this method in 15 irradiated head and neck cancer 
patients displayed an S-curve reflecting a symptomless first irradiation week, 
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followed by a rapid and steady increase of white discoloration, erythema and 
pseudomembranes during the second and third week. Oral candidiasis, generalized 
symptoms such as weight loss and the highest mucositis scores were seen after 3 
weeks irradiation. The novel mucositis scoring method may be of value in 
studying the effect of hygiene programs, topical application of disinfectants or 
antibiotics on oral mucositis. 
 
  Durmus Etiz et al (2002) 13 stated that aggressive cancer treatment may 
have toxic effects on normal cells as well as cancer cells. Radiation induced 
mucositis is the most important acute side effect in patients undergoing 
radiotherapy for head and neck malignancies. There are number of scoring 
systems, although none is universally accepted and all lack standardization. A 
prospective study was conducted to evaluate the validity and reproducibility of 5 
different mucositis scoring systems. The samples were 43 patients with head and 
neck malignancies who had been irradiated were evaluated. 5 different mucositis 
scoring systems which included WHO, Radiation Therapy Oncology Group, 
“Hickey”, “Van deer Schueren” and “Makkonen” were compared with each other. 
It was concluded that all scoring systems were equally valid and the exact grading 
of mucositis can be achieved by combining clinical information about pain and 
nutritional status with oral mucosal reactions. 
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Relation Between alcohol and alcohol containing mouthwashes 
and oral and pharyngeal cancer  
  Weaver et al (1979) 40 in his study among 200 patients with squamous cell 
cancer of the head and neck, 11 persons abstained from all alcoholic beverages 
and tobacco. All but one of these 11 patients had used mouthwash many times 
daily for more than 20 years. Most of them used a brand of mouthwash that 
contained 25% alcohol. This evidence, along with information from other patients, 
may be used to confirm or refute the theory that mouthwash may be carcinogenic 
for susceptible persons. 
  Bolt et al (1983) 2 conducted a case-control study in North Carolina a part 
of it, involving 206 women with oral and pharyngeal cancers and 352 controls, 
questions were asked concerning the patterns of mouthwash use. No significant 
overall increase in risk was found among users; the relative risk, adjusted for snuff 
dipping and smoking habits, was 1.15 [lower, upper limits of the 95% confidence 
interval (95% Cl) = 0.8, 1.7]. The relative risk associated with mouthwash use was 
increased to 1.94 (95% Cl = 0.8, 4.7), however, among women abstaining from 
tobacco. Although consistent dose-response relationships were not observed for 
this subgroup, these findings and other reports of an increased risk among persons 
ordinarily at low risk of this disease raise the possibility that mouthwash may 
contribute to oral and pharyngeal cancers.                    
  Wynder et al (1983) 43 conducted a retrospective study to evaluate the role 
of mouthwash and other factors in relation to oral cavity cancer. Daily use of 
mouthwash showed an excess risk in females but no excess risk in males. No dose 
response was seen in females with increased duration of use. In nonsmoking, 
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nondrinking women as well, daily mouthwash use was associated with excess 
risk. Multiple logistic regressions including all factors of interest showed 
inconsistent results for duration and frequency of mouthwash use. Due to the 
absence of a dose-response relationship and the possibility of confounding by 
tobacco and alcohol use, it was not possible to attribute causal significance to the 
association between daily mouthwash use and oral cancer in women.                    
 
  Mashberg A et al (1985) 23 studied the relationship between alcohol and 
oral and pharyngeal cancer. 96 patients with oral and pharyngeal cancer and 986 
control patients were interviewed regarding mouthwash use, commercial brand of 
mouthwash frequently used, alcohol and tobacco consumption, and demographic 
characteristics. Analysis of results showed use of mouthwash was not significantly 
different between those with oral and pharyngeal cancer and control group. 
Similar results were also observed in patients with similar smoking habits, and 
those who consumed alcohol. Thus this study demonstrates little association 
between use of mouthwash and oral and pharyngeal cancers. 
 
  Deborah M. Winn et al (1991) 42 in their survey on mouthwash (alcohol 
containing) use and oral conditions in the risk of oral and pharyngeal cancer 
interviewed 866 patients with cancer of the oral cavity and pharynx and 1249 
controls of similar age and sex from the general population in 4 areas of the united 
states since tobacco smoking and alcohol consumption were the primary causes 
for oral and pharyngeal cancer in the United States. Risk of oral cancer was 
elevated by 40% among male and 60% among female mouthwash users, after 
adjusting for tobacco and alcohol consumption. It was found that risks among 
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both sexes increased equally in duration and frequency of mouthwash use and 
were confined to users of mouthwash high in alcohol content. It was concluded 
there is an association between mouthwash containing alcohol and oral cancer. 
 
  Winn DM et al (1991) 42 evaluated oral health practices and use of alcohol 
– containing mouthwashes as risk for developing oral and pharyngeal cancers. 
Data was collected by a structured questionnaire from 1114 oral cancer cases and 
1268 controls regarding tobacco use, alcohol use, diet, occupation and oral health 
status. Analysis of results showed 49% of males and 58% of females among the 
cases used mouthwash, the corresponding sex – specific OR { odds Ration } being 
1.4 and 1.6, thus revealing a statistically significant increase in risk associated 
with regular mouthwash use. The risk tended to increase with increasing duration 
and frequency of mouthwash use and according to the alcohol concentration of 
mouth wash. 
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Use of mouthwashes in patients undergoing radiotherapy for head 
and neck malignancies      
  Samaranayake LP et al (1988) 29 in his single- blind study compared the 
efficacy of benzydamine and chlorhexidine in alleviating irradiation-induced 
mucositis in two groups of patients undergoing post-operative radiotherapy for 
squamous carcinoma of oral activity. In addition, quantitative and qualitative 
assessment of some oral flora was also done. 25 patients were randomly allocated 
to use either benzydamine or chlorhexidine mouthwashes twice daily for 6 weeks. 
Mucositis and pain was measured subjectively along with microbial samples taken 
by oral rinse technique every week. Analysis of results showed no significant 
difference in the overall mucosal rating. However 12 out of 13 patients using 
benzydamine recorded oral discomfort while washing the mouth as compared with 
7 out of 12 in chlorhexidine group. There was no significant difference between 
the carriage rate of yeasts, coliforms and staphylococcus aureus when using the 
different mouthwashes. This study concludes that though there is little difference 
between the mouthwashes, chlorhexidine is preferable to patients. 
 
  Spijkervet FKL et al (1989) 32 did a prospective, double – blind, 
randomized, placebo-controlled study to find out the effect of chlorhexidine 0.1% 
rinses on viridians streptococci and yeasts, as well as enterobacteriaceae, 
pseudomonadaceae, and Acinetobacter spp, and staphylococci in 30 patients with 
cancer of the head and neck with identical radiation portals to the oropharyngeal 
areas. After a dental treatment deemed necessary to eliminate foci of infection or 
mechanical irritation, half of the patients rinsed and sprayed a chlorhexidine 0.1% 
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solution, while the other half with a placebo. The patients rinsed their mouth, for 1 
minute, three times a day. Mucositis was evaluated and thrice weekly afterwards. 
Oropharyngeal cultures were also obtained at similar intervals by oral washing 
with isotonic saline solution and incubated at 37o C for 18 hours. 
  Analysis of results showed that except for viridans streptococci, no 
significant difference was observed in the number of carriers and oral 
concentration among the two study populations. There was also no difference in 
the development and severity of oral mucositis between the two groups, thus 
demonstrating that 0.1% chlorhexidine rinse neither reduces the oropharyngeal 
flora nor the development and severity of oral mucositis. 
 
  Epstein JB et al (1989) 12, in his study, evaluated the effect of 
chlorhexidine rinse in 50 patients undergoing radiation therapy to the head and 
neck region and developed xerostomia. At the initial visit a complete dental 
evaluation and salivary flow rate data were collected. The Decay Missing Filled 
Surface [DMFS] was determined and saliva was submitted for determination of 
salivary count of S. mutans and lactobacillus species. High caries risk patients 
rinsed twice daily with 0.2% chlorhexidine gluconate in addition to application of 
neutral 0.5% sodium fluoride gel once daily. Patients were seen up to 26 times 
over a period of up to 3 years and salivary flow rate tests and bacteriologic study 
were repeated. Results showed a moderate reduction of S. mutans but limited 
response of lactobacillus to chlorhexidine rinse in conjunction with fluoride 
application.  
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    Ferretti GA et al (1990) 15 did a double – blind randomized study to find 
efficacy of chlorhexidine mouth rinse in oral mucositis reduction in patients with 
cancer receiving either radiotherapy to the head and neck or intensive systemic 
chemotherapy. 70 patients, who completed the study were randomly assigned to 
use a mouth rinse containing either 0.12% chlorhexidine digluconate or a control 
rinse identical in composition but without chlorhexidine. Patients were instructed 
to swish vigorously and gargle 15ml of mouth rinse for 30 seconds, thrice a day 
for 21 days. They were followed up 1 week after the uses of mouth washes were 
stopped. Mucositis was scored and oral microbial assessment was done at 
baseline, 7, 14, and 21 days and one week after discontinuation of mouth rinses. 
Analysis of results showed that treatment- associated oral soft tissue inflammation 
and ulceration can be significantly reduced in patients undergoing chemotherapy 
by using chlorhexidine. However little or no reduction of mucositis was observed 
in patients receiving high-dose head and neck radiation therapy. 
 
  Carl W and Emrich LS (1991) 5 determined whether  a specific oral care 
with Kamillosan Liquidum oral rinse would reduce and/or prevent the severity of 
radiation-induced mucositis in 20 patients scheduled to receive radiotherapy. 
Kamillosan Liquidum solution is prepared from the flower of the chamomile 
plane. The main constituents are chamazulene, levomenol, polyins, and 
flavonoids. The patients, after an oral examination, were instructed to use 10 to 15 
drops of Kamillosan rinse in approximately 100ml of warm water at least 3 times 
a day along with cleaning the teeth and soft tissue with toothettes. The oral tissue 
changes were recorded daily for inpatients and during every clinic visit to out 
patients. Tissue changes were assessed on a scale of 0 to 3: measurements of pH 
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of oral fluids were made, as well as intraoral photographs were taken. Analysis of 
results showed that though one patient assigned Kamillosan Liquid mouthwash 
developed grade 3 mucositis, most patients who used conventional oral care with 
5% sodium bicarbonate, saline and 3% hydrogen peroxide developed grade 3 
mucositis, thus showing that Kamillosan oral rinse will prevent or reduce tissue 
inflammation and desquamation. 
 
  Toljanic JA et al (1992) 37, in his study, evaluated and quantified the level 
of substantivity of chlorhexidine in individuals who had received cancericidal 
doses of radiation for tumors of head and neck. Six patients, previously treated 
with primary or adjunctive radiotherapy were instructed to vigorously rinse with 
½ oz. of .12% chlorhexidine rinse for 30 seconds, after which they were instructed 
to expectorate. This was followed exactly 1 minute later by a second aqueous 
rinse of 1% acetic acid, which was again expectorated. The procedure was then 
repeated twice during which the time interval between the 0.12% chlorhexidine 
rinse and 1% acetic acid rinse was changed to 1 and 4 hours respectively. The 
expectorated acetic acid was neutralized and incubated for 18 to 24 hours in media 
plates containing trypticase soy agar seeded with test organism [S. epidermidis]. 
 
 Measurable zones of inhibition were noted with all cycles for five of the 
six subjects, showing that when 0.12% chlorhexidine is used as an oral rinse in 
patients irradiated for certain tumors of head and neck, an antibacterial element is 
retained and gradually released into the oral cavity over time. 
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  52 patients participated in the multi-institutional placebo-controlled, 
randomized clinical trial by Foote RL et al (1994) 16 to determine whether a 
chlorhexidine mouthwash could alleviate radiation-induced oral mucositis. 
Patients were randomized equally among the following three treatment groups: 
i. Chlorhexidine mouthwash, 15ml four times a day throughout the 
period of radiation therapy and 2 weeks thereafter, 
ii. Placebo mouthwash, used in the same schedule, 
iii. Oral non-absorbable antibiotic lozenge containing amphotericin B, 
tobramycin and polymyxin E 
  Oral mucositis was graded according to World Health Organization 
criteria at baseline and at weekly intervals. In addition, patients were requested to 
fill out questionnaires on a weekly basis and 4 weeks thereafter. Analysis of 
results showed slightly more stomatitis and side effects in the chlorhexidine 
patients, thus ruling out the possibility that chlorhexidine can lower the average 
daily mucositis score. 
 
  Feber T (1996) 14, in his study, randomized patients undergoing radical 
radiotherapy treatment (55-60Gy in 4 weeks) to more than 50% of the oral cavity 
and oropharynx based on a oral care protocol with either saline 0.9% or hydrogen 
peroxide 3.5 volumes (HP) as rinses. The results of his study showed that, on 
average, the group receiving saline rinses appeared to do better on some outcomes 
than the group receiving HP. This suggested that frequent mechanical cleansing of 
the mouth may be more important than the antiseptic properties of a mouthwash. 
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  Rahn R et al  (1997) 25,  in his monocentric, open, placebo- controlled and 
randomized clinical trial, enrolled 40 patients and randomly assigned them to a 
treatment or control group [20 patients each]. During radiation therapy, all 
patients received mucositis prophylaxis with nystatin, dexpanthenol, rutoside and 
immunoglobulin. In addition, patients of the treatment group performed 4 times 
daily rinsing (3min, each) with 100ml povidone-iodine solution from the 
beginning to 1 week after the end of radiation therapy. Patients of the control 
group rinsed with sterile water in the same way. Clinical examination of oral 
mucosa was performed before starting radiation therapy and weekly during 
radiation therapy until 2 weeks after the end of therapy. A last examination took 
place 6 weeks after the end of therapy. Mucositis was graded according to WHO 
recommendations. Analysis of results showed oral mucositis in 14 patients of the 
treatment group and in all 20 patients of the control group. The mean onset of 
mucositis was after 2.25 weeks in treatment group and 1.5 weeks in control group. 
The severity of mucositis was also statistically significant between the two groups. 
Thus the present study demonstrates that rinsing with povidone-iodine- in addition 
to a standard prophylaxis regimen reduces the incidence, severity and duration of 
radiation induced oral mucositis. 
 
  Adamietz IA et al (1998) 1 investigated the efficacy of prophylactic oral 
rinsing with povidine-iodine solution in a prospective randomized study of 40 
patients scheduled to undergo radiochemotherapy of head and neck region. During 
radiation therapy, all patients received mucositis prophylaxix with nystatin, 
dexpanthenol, rutosides and immunoglobins. In addition, 20 patients in treatment 
group performed rinsing 4 times daily (3 min. each) with 100 ml povidone- iodine 
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solution while 20 patients in control group rinsed with sterile water in the same 
way. The severity of mucositis was defined according to the WHO 
recommendations and clinical examination was done before commencing 
radiation therapy, every week during radiation therapy and 2 and 6 weeks after the 
end of radiation treatment. Analysis of results showed a statistically significant 
higher grade of mucositis in control group. The onset of mucositis was also 
significantly later in povidone-iodine group with a faster recovery, thus 
demonstrating that povidone-iodine group, in addition to a standard prophylaxis 
regimen- reduces incidence, severity and duration of radiation-induced oral 
mucositis. 
 
  Marylin J Dodd et al (2000) 9 conducted a randomized clinical trial for 
evaluating the effectiveness of 3 commonly used mouthwashes to treat 
chemotherapy-induced mucositis. The study consisted of 200 patients from 23 
patient and office settings who were undergoing stomatotoxic chemotherapy and 
were monitored from the time they developed mucositis until cessation of the 
signs and symptoms of mucositis or until they finished their 12 day supply of 
mouthwash. All patients were randomly assigned a mouthwash (salt and soda, 
chlorhexidine and “magic” mouthwash (lidocaine, Benadryl and Maalox). The 
nurses used the oral assessment guide for initial assessment and patients were 
taught how to assess their own mouth and the nurses phoned the patients every 
day to gather status reports among the 200 patients, there was cessation of signs 
and symptoms of mucositis within 12 days and there was no significant difference 
between the 3 compared groups and the authors concluded that with the given 
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comparable effectiveness of the mouthwashes, the least costly was salt and soda 
mouthwash. 
 
  Borrajo GLL et al (2002) 4 evaluated the efficacy of an alcohol- free 
chlorhexidine mouth rinse to the same preparation with 11% ethanol and a 
placebo. 97 patients were included in the study and were divided into 3 groups. 
They were asked to rinse one of the following mouth rinse: 0.12% chlorhexidine 
gluconate, 0.05% soldium fluoride and 11% ethanol:  the same chlorhexidine 
formulation without ethanol: and a placebo,for 30 seconds with 10ml of undiluted 
mouth rinse once a day for 27 days. Baseline plaque and papillary bleeding index 
were recorded and repeated at 14 and 28 days. Analysis of results showed 
significant reduction in baseline plaque and papillary bleeding in both 
chlorhexidine groups when compared placebo, though there was no difference 
between them, showing that chlorhexidine mouth rinses with or without alcohol 
reduces plaque levels. 
 
  In this study, Dodd NJ et al (2003) 10 hypothesized that if the particles in 
the original sucralfate suspension were micronized (i.e., < or =25microns) then the 
coating action of the mouthwash in the oral cavity would be enhanced. The 
purpose of this pilot study was to compare the efficacy of micronized sucralfate 
(Carafate R) mouthwash and salt and soda mouthwash in terms of the severity of 
the mucositis, the severity of mucositis-related pain, and the time required to heal 
radiotherapy-induced mucositis in patients with head and neck cancer. Severe 
mucositis and related pain can interfere with the ingestion of food and fluids, so 
patients body weight were measured as well. All patients in this randomized 
 
Review of Literature   
 
 
 32
clinical trial carried out a systematic oral hygiene protocol called the PRO-SELF: 
mouth aware (PSMA) program. Patients who developed radiation-included 
mucositis anytime during their course of radiotherapy (RT) were randomized to 
one of the two mouthwashes and followed to the completion of RT and at one 
month following RT. Two referral sites were used for the study. Repeated 
measures occurred with the following instruments/variables: MacDibbs mouth 
assessment and weight. Demographic, disease and cancer treatment information 
was also obtained. Thirty patients successfully completed the study. No significant 
differences were found in the number of days to onset of mucositis (i.e., 16+/-8.4 
days). When patients had their worst MacDibbs score, (i.e., most severe 
mucositis), there were no significant differences between the mouthwashes as to 
MacDibbs score, the RT dose received, are rating of pain (upon swallowing). 
Similarly, at the end of RT, no significant differences were found between 
mouthwashes as to MacDibbs score are ratings of pain (upon swallowing). At the 
one –month follow up assessment, no significant differences were found between 
the mouthwashes in MacDibbs scores are pain ratings (upon swallowing). The 
analysis of the efficacy of the two mouth washes revealed no significant 
differences in the time to heals (in days) from the RT- induces mucositis. The 
findings from this trail provide important clinical information regarding cost 
analysis of RT mucositis management. Given that there is no significant 
difference in efficacy between micronized sucralfate and salt and soda, use of the 
less costly salt and soda is prudent and cost effective.  
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  PD. Kumar Madhan, PS. Sequeira, Kamalaksha Shenoy, Jayaram 
Shetty (2008) 19 conducted a randomized control trial on comparing the effect of 
three alcohol free mouthwashes on radiation-induced oral mucositis in patients 
with head and neck malignancies. The study group consisted of 80 patients with 
head and neck malignancies scheduled to undergo curative radiotherapy. They 
were randomly assigned to receive one of the 3 mouthwashes (0.12% 
chlorhexidine, 1% povidone-iodine or salt/soda) or a placebo which was taken as 
a control. The patients were instructed to rinse with 10ml of the mouthwash, twice 
daily, for a period of 6 weeks. Mucositis was assessed at baseline and at weekly 
intervals during radiation therapy based on WHO criteria for grading of mucositis. 
The baseline values of the 4 groups were matched for age, sex, stage of cancer. A 
post hoc test for repeated measures was used to find the difference of mean 
mucositis scores between the groups at various week intervals. It was found that 
povidone-iodine mouth wash had better results compared to the other groups and 
the placebo and it was concluded that it can reduce the severity and delay the 
onset of oral mucositis due to therapeutic radiotherapy. 
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                   This study was conducted between April 2008 to March 2009 in the 
department of Oral Medicine and Radiology of Ragas Dental College and 
Hospital, Dr. Rai memorial medical and Cancer Centre and Cancer Shelter, 
Chennai.  
 
Study Design: 
The present study is a placebo controlled and randomized controlled trial. 
 
Study population: 
  60 patients with head and neck malignancies, scheduled to undergo chemo 
radiotherapy at Dr. Rai memorial medical and cancer centre and cancer shelter, 
Chennai were enrolled in the present study and randomly assigned to the test or 
control groups (15 patients each). 
 The inclusion and exclusion criteria are as follows. 
 
Inclusion criteria: 
1. Patients should be above 18 years of age. 
2. Patients should have head and neck malignancies of stage III and stage IV, 
according to TNM classification. 
3. Patients should be scheduled to receive chemo radiotherapy at Dr. Rai 
memorial medical and cancer centre and cancer shelter, Chennai. 
4. The planned radiation dose should be equal to or exceed 60Gy, delivered 
at 30 fractions, spread over a 6 week period. 
 
Materials and Methods   
 
 
 35
5. The patients who take cisplatin and 5-fluorouracil along with radiotherapy 
for 21 days with 2 cycle each. 
6. Atleast one third of the oral cavity mucosa should be included in the 
radiotherapy field. 
7. Patient should be able to read, and/or understand and sign the informed 
consent. 
Exclusion criteria: 
1. Patients with open mouth sores at study entry. 
2. Patients who had undergone prior radiotherapy or chemotherapy. 
3. Patients with HIV infections, diabetes mellitus, or hyperthyroidism. 
4. Patients who are allergic to any used mouthwashes. 
5. Patients using other prophylactic mouthwashes. 
6. Patients who are pregnant. 
7. Patients who required use of any form of treatment/medicaments (eg., 
antibiotics, analgesics, etc.) during the course of radiotherapy because of 
exacerbation of symptoms. 
External beam radiotherapy: 
  The purpose of radiotherapy is to deliver a uniform dose of radiation to the 
tumor mass, while the dose received outside of the tumor zone is minimized.  
  At Dr. Rai memorial medical and cancer centre and cancer shelter, 
Chennai, external beam radiotherapy is used to treat patients with head and neck 
malignancies. Cobalt 60 is used as the radioactive source that emits gamma rays at 
an average energy level of 1.2 MeV. In addition, moulds are made for all head and 
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neck malignancy patients undergoing radiotherapy for immobilization of their 
head during radiation. 
 
  These patients received external bilateral irradiation, 2 Gys daily, for a 
total dose of 60 Gys: the doses given five days a week over a period of 6 weeks. 
The irradiation portals were such that the major salivary glands (parotid and 
submandibular) were included. Radical resection or de bulking of the primary 
tumor often preceded the course of irradiation.   
                      
   Along with radiotherapy, anticancer drugs such as 100mg/m2 of cisplatin 
was given on the first day followed by the second dose on the twenty second day 
and third on the forty third day and 600mg/m2 of 5-fluorouracil was administered 
continuously for first five days on weeks one and six respectively (Intravenously). 
 
Mouth Washes: 
                         The effect of three test mouthwashes and a control were assessed 
in the present study. The mouthwashes assessed were: 
1. 0:12% chlorhexidine 
2. Salt / sodium bicarbonate 
3. ‘magic’ mouthwash 
4.  Plain water [control] 
                        Other ingredients like coloring agents, sweeteners, flavouring 
agents were added to the mouthwash so that all of them have identical colour and 
acceptable taste. All the mouthwashes were alcohol – free and were prepared at 
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Mankind Pharma, New Delhi-20. The mouthwashes were numbered randomly 
from 1 to 60 by the mouth wash manufacture.  
 
  The coding was done by the manufacturer and the four different solutions 
were known only to him. It was later deciphered to the investigator at the end of 
the study. 
 
The compositions of the dispended mouthwashes were as follows: 
0.12% chlorhexidine mouthwash 
                Chlorhexidine gluconate             0.12% 
                Sodium lauryl sulphate             0.1% 
                Water              100% 
                Amaranth red                         QS 
                Saccharin               QS 
 
Salt / Sodium bicarbonate mouthwash 
                 Sodium Chloride           0.4% 
                 Sodium bicarbonate                    1% 
                 Sodium lauryl sulphate         0.1% 
                 Water          100% 
                 Amaranth red          QS 
                 Saccharin           QS 
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“Magic”mouth wash 
                  Lignocaine solution                                0.5%   
                 Diphenhydramine hydrochloride         0.0132% 
                 Aluminium hydroxide suspension       14.75 ml   
                                                                         (Maalox) 
                  Sodium lauryl sulphate           0.1% 
                   Water      100% 
                   Amaranth red                        QS 
                   Saccharin               QS          
 
Plain water [control] 
                    Water      100% 
                    Amaranth red          QS 
                    Saccharin                 QS 
                    Peppermint essence                QS 
 
QS=Quantity Sufficient 
  They were dispended in identical looking 500ml coded glass bottles 
having a lid with marking for 10ml. 
 
Oral Care Instructions: 
    All patients who participated in the study had an oral examination before 
initiation of chemoradiotherapy. The possible oral soft tissue reactions of their 
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oncologic treatment were explained as well as the expected benefits of the oral 
care. Informed consent was obtained from the patients. 
 
Patient Grouping: 
60 patients, who met with the inclusion /exclusion criteria were selected 
for the study and were randomly assigned to one of the four groups. The patients 
were numbered 1 to 60 randomly.  The patient who was assigned a particular 
number was also given the same numbered mouthwash. Once the mouthwash was 
over it was replaced with the same numbered mouthwash.  
 
The patients were instructed   to rinse 10ml [measured by marking in the 
lid] of the mouthwash, twice a day (morning and night after brushing) for a period 
of 6 weeks. They were asked to swish the mouthwash for about 2minutes and then 
expectorate. They were requested to do the above, after food and to abstain from 
eating and gargling the mouth for half an hour after use of mouthwash. The 
patients were initially dispended a 500ml bottle and a second bottle was given 
after third week. 
 
Patient compliance was assessed with regard to the regular usage of 
mouthwash by checking the level of mouthwash left in the bottle provided to 
determine whether the mouthwash had been used regularly or not used due to 
certain reasons such as the taste, odour during the weekly assessments. 
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Assessment of Mucositis: 
   Mucositis was assessed using the World Health Organization grading of 
Mucositis, as it is the most common scale used to assess Mucositis severity. The 
oral cavity was divided into 8 distinguishable areas: buccal mucosa [left and 
right], soft and hard palate, dorsum and border of the tongue [left and right] and 
the floor of the mouth. Mucositis score of maximally affected area is recorded.  
 
The WHO grading of Mucositis is as follows: 
 
Grade 0 No symptom. 
Grade 1 Soreness and erythema. 
Grade 2           Erythema, ulcers; can eat solid foods. 
 Grade 3 Ulcers, requires liquid diet only.  
 Grade 4     No possible alimentation. 
 
  This scoring system includes objective changes (erthema, ulceration), 
subjective symptoms (pain) and functional consequences (dysphagia). The later 
two were assessed by questioning the patient. 
 
  Assessment of Mucositis was done at base line, and after each week of 
chemo radiation therapy [6 weeks]. Examinations of patients were done under 
standard illumination.  
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 The following armamentarium was used for examination of patients: 
1. Gloves and mouth masks 
2. Mouth mirror 
3. Tweezer 
4. Sterile gauze pieces 
5. Kidney tray, to place the instruments. 
6. Tongue depressor 
7. Laryngoscope 
 
  The patients were examined using proper aseptic measures and only sterile 
instruments were used for examination.  All Patients who participated in this study 
were assigned separate files [which consisted of inclusion/exclusion form, 
informed consent -recording form] for ease maintenance of data. 
 
Calibration of the Examiner: 
  Calibration of examiner in WHO grading of oral Mucositis was done 
before the start of the study. The assessments done by the examiner before and 
during the study were monitored by the staff that was not a part of the study. After 
completion of the study, the code of the mouthwashes was broken. The results 
were tabulated and statistically analyzed. 
 
Statistical Analysis: 
  The results were analyzed using SPSS for windows version 10.0. The null 
hypothesis for the current study was that there would not be any difference 
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between the test groups and the control in the onset and severity of chemo 
radiation-induced oral mucositis in patients with head and neck malignancies. The 
primary endpoint of the study was to dtrmin mucositis at the end of the sixth 
week, after the termination of chemo radiotherapy for patients with head and neck 
malignancies. 
 
  Further, the present trial was designed to have a power of 90% and alpha 
level of significance (type 1 error) was fixed as 0.05, i.e., the null hypothesis was 
rejected if the p value was less than this value. The standard difference in the 
mean mucositis scores between the test and the control arms was assumed from an 
earlier study as 1.14. However, the standard difference in the mean mucositis 
scores between the test arms was considered negligible in the present study. 
Lehr’s formula was used to calculate the sample size for the power of 90% and a 
two-sided significance level of 0.05. 
 
  The baseline demography of the four groups was matched for age, sex, 
stage of cancer and whether patients had cancer of oral or extra-oral region. The 
former was assessed using ANOVA while the rest were analyzed using Chi-
square test. 
 
  A post hoc test for repeated measures was used to find the difference of 
mean Mucositis scores between the groups at various week intervals.  
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STUDY OUTLINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study population consisted of patients with 
head & neck malignancies, scheduled to 
undergo chemo radiotherapy at Dr. Rai 
memorial medical and cancer centre & 
cancer shelter, Chennai (n= 88)
Patients who fulfilled the 
inclusion/exclusion criteria and gave 
voluntary consent to participate in the 
trial (n=60) 
Non participants (n=28) not 
meeting the criteria & 
refusing to participate 
Randomizatio
Allocation 
Group I: 
0.12% 
chlorhexidine 
(n=15) 
Group II: 
salt/sodiumbic
-arbonate 
(n=15) 
Group III: 
“magic” 
mouthwash 
(n=15) 
Group IV: 
plain water 
(control) 
(n=15) 
Follow-up 
& Analysis 
Group I: 
Analyzed 
(n=15), 
Excluded from 
analysis (n=0) 
Group II: 
Analyzed 
(n=15), 
Excluded from 
analysis (n=0) 
Group III: 
Analyzed 
(n=15), 
Excluded from 
analysis (n=0) 
Group IV: 
Analyzed (n=15), 
Excluded from 
analysis (n=0) 
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RAGAS DENTAL COLLEGE & HOSPITAL 
2/102, EAST COAST ROAD, Uthandi, Chennai – 600119 
DEPARTMENT OF ORAL MEDICINE & RADIOLOGY 
PROFORMA FOR STUDY TO COMPARE THE EFFICACY & 
EFFECTIVENESS OF THREE COMMONLY USED MOUTHWASHES 
TO TREAT CHEMORADIOTHERAPY INDUCED MUCOSITIS 
                                                                                                                         Date: 
S.No: 
Op.No:        
Name:                                                                                            Age/Sex: 
Address: 
 
Phone number: 
Occupation: 
Monthly income: 
Chief complaint: 
History of presenting illness: 
Past medical history: 
Past surgical history: 
Past dental history: 
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Personal habits: 
- Chewing habits (Duration/ Frequency) 
- Smoking  (Duration / Frequency) 
- Alcohol consumption (Duration / Frequency)                                                
                                                             
General examination: 
- Height / Weight:                   / 
Local examination: 
- Extra oral (Examination of lymph nodes) 
                                                         -  Number of nodes 
                      -  Consistency 
                      -  Warmth 
                      -  Tenderness 
                      -  Mobile / Fixed 
 
- Intra oral 
            Gingival 
Labial & buccal mucosa 
Alveolar mucosa 
Tongue 
Palatal mucosa 
Floor of the mouth 
Teeth 
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Diagnosis: 
TNM stage:      Stage I 
                          Stage II 
                          Stage III 
                          Stage IV 
Chemotherapy prescription: 
Radiotherapy prescription:                      Gy in             # in             weeks 
Radiotherapy delivered with:      Telecobalt / Linac 
Mouthwash:          bottle number -  
Any side effect perceived: 
Protocol completed:              yes / no 
Subjective symptoms:  Pain ( I / II / III / IV / V / VI weeks)  
                                       Dysphagia (I / II / III / IV / V / VI weeks) 
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WHO index for grading chemo radiation- induced oral mucositis 
 
 
 
 Baseline 1st 
week 
2nd 
week 
3rd 
week 
4th 
week 
5th 
week 
6th 
week 
Buccal 
Mucosa (R) 
       
Buccal 
Mucosa (L) 
       
Soft Palate        
Hard Palate        
Dorsum of 
Tongue 
       
Lateral 
Border of 
tongue(R) 
       
Lateral 
Border of 
tongue(L) 
       
Floor of 
Mouth 
       
Score        
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CONSENT FORM 
                           I, ___________________________________ , the undersigned 
hereby give my consent for participation as a subject in the study titled “TO 
COMPARE THE EFFICACY AND EFFECIENCY OF THREE COMMONLY 
USED MOUTHWASHES TO TREAT CHEMORADIOTHERAPY INDUCED 
MUCOSITIS” conducted by Dr. P. Jagathesh under the guidance of Capt. Dr. S. 
Elangovan. Professor, Dept. of Oral Medicine & Radiology, Ragas Dental College 
& Hospital, Chennai. 
 
   I have been counseled about this study and as a part of this study protocol 
I unconditionally and freely give my consent to participate in this study. 
 
Date: 
Place:                                                                                                                            
Signature 
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Of the total 88 patients who reported to Dr. Rai memorial medical and 
cancer centre and cancer shelter for treatment of head and neck malignancies, 60 
patients, who fulfilled the inclusion criteria, participated in this trial and were 
Randomly allocated into four groups.  
 
Table – I: Distribution based on number of patients who completed the study 
in each group 
                       The study group consisted of a total number of 60 patients who 
completed the study.  Out of the 60 patients, 15 patients were randomly divided 
into four groups of 15 each. 15 patients in chlorhexidine group, 15 patients in 
salt/sodium bicarbonate group, 15 in “magic” mouthwash group and 15 as control 
group.                         
 
Table – II: Distribution of patients in Chlorhexidine group 
                       In the chlorhexidine group the males predominated than the females 
with the ratio of 17:3. The most commonly seen type of cancer was cancer of the 
tongue (3) all being males with the age of 45, 56 and 57 followed by cancer of the 
buccal mucosa (2) and both being males of age 51 and 61, tonsil(2) in which 1 
being a male at the age of 72 and a female at the age of 61, pyriform fossa (2) and 
both were males of age 55 and 63, and alveolus which consisted of males of age 
56 and 61 (2) followed by the cancer of the epiglottis (1) who was a male of 58 
years of age, a male of 49 years had cancer of the oropharynx (1), a female of 52 
years had cancer of the nasal cavity (1)  and a male of age 49 with cancer of 
maxillary antrum (1).               
 
 
Results   
 
 
 50
Table – III: Distribution of patients in Salt/Sodium bicarbonate group 
    In the salt/sodium bicarbonate group the males predominated than the 
females with the ratio of 17:3. The most commonly seen type of cancer was 
cancer of the tongue (6) among them 5 being males with the age of 48, 54, 58, 64 
and 71 and 1 being a female of 51years followed by cancer of the buccal mucosa 
(2) and both being males of age 61 and 69, tonsil(2) both being males at the age of 
48 and 64, pyriform fossa (1), a male of 39 years followed by the cancer of the 
epiglottis (1) who was a male of 52 years of age, a male of 59 years had cancer of 
the larynx (1), a female of 67 years had cancer of the vocal cords (1)  and a female 
of age 49 with cancer of the posterior pharyngeal wall (1). 
 
Table – IV: Distribution of patients in “magic” mouthwash group 
                        In the “magic” mouthwash group the males predominated than the 
females with the ratio of 16:4. The most commonly seen type of cancer was 
cancer of the tongue (3) 2 being males with the age of 52 and 62 and 1 being a 
female of age 43 and tonsil (3) all being males of age 41,53 and 61followed by the 
cancer of the buccal mucosa (2) and both being a males of age 56 and 73,  
pyriform fossa (2) and both were males of age 49 and 69 followed by the cancer 
of the epiglottis (1) who was a male of 70 years of age, and alveolus which 
consisted of a female of age 58 (1) a male of 48 years had cancer of the 
oropharynx (1), a female of 71 years had cancer of the supra glottis (1)  and a 
female of age 59 with cancer of hypopharynx (1). 
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Table – V: Distribution of patients in Control group 
                       In the control group the males predominated than the females with 
the ratio of 15:5. The most commonly seen type of cancer was cancer of the 
tongue (4) 2 being males with the age of 54 and 60 and 2 being females of age 58 
and 67 followed by cancer of the buccal mucosa (3) 2 being males of age 49 and 
59 and females of age 41, tonsil(2) in which both being males at the age of 43 and 
65 followed by  cancer of pyriform fossa (1) who was a male of age 71, and 
alveolus(1) which consisted of a male of age 55 followed by the cancer of the 
epiglottis (1) who was a female of 50 years of age, a male of 69 years had cancer 
of the supraglottis (1), a female of 61 years had cancer of the posterior pharyngeal 
wall (1)  and a male of age 58 with cancer of maxillary antrum (1). 
 
Table – VI: Distribution of patients in the four groups based on sex 
            In all the groups, the number of males exceeded the females. 
Maximum number of males was present in chlorhexidine and salt/sodium 
bicarbonate group [80%] and control group had the minimum [66.6%]. The 
number of males in “magic” mouthwash group was [73.3%]. There existed no 
statistically significant difference between the groups based on sex distribution 
with p value 0.122. 
 
Table – VII: Distribution of patients in the four groups based on age 
            The mean age of patients in chlorhexidine and salt/sodium 
bicarbonate group were 56.93 and ranged between 45 - 72 and 48-71 years 
respectively. The mean age of patients in “magic” mouthwash group was 57.66 
which ranged between 41-71 years and 57.73 was the mean age of patients in 
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control group, ranged between 41-71 years. The overall mean age of the patients 
who completed the study was 57.32 and range between 41-72 years. Using 
ANOVA test, it was found that there existed no statistically significant difference 
between the age of patients in four groups with p value 0.569. 
 
Table – VIII: Distribution of patients in the four groups based on the location 
of cancer 
           Cancer of tongue [26.67%] was the most common diagnosis among 
the patient, followed by cancer of buccal mucosa and tonsil [15%]. Other 
locations of cancer include the alveolus, epiglottis [6.67%], hypo pharynx, larynx, 
nasal cavity & vocal cords [1.67%], oropharynx, posterior pharyngeal wall, 
maxillary antrum & supraglottis [3.33%] and pyriform fossa [10%]. 
 
Table – IX: Distribution of patients in the four groups based on cancer of 
oral cavity or extra-oral region 
For better understanding the patients in the four groups were divided into 
those cancers of oral cavity and those having cancer of extra-oral region. Cancer 
of extra-oral region was all the groups and accounted for 31cases, among the total 
completed cases. It was maximum in the “magic” mouthwash group [09], 
followed by chlorhexidine [08] and salt/sodium bicarbonate and control groups 
[07 each]. Among the 29 patients who had cancer of oral cavity, maximum 
belonged to salt/sodium bicarbonate and control groups [08 each], 07 in 
chlorhexidine group followed by the “magic” mouthwash group [06]. No 
statistically significant difference was found between the groups based on the 
location of cancer with p value 0.688. 
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Table – X: Distribution of patients in the four groups based on stage of 
cancer: 
The patients were also grouped based on the staging of cancer, according 
to TNM classification. Among the total patients, 31 had stage IV cancer and 29 
had stage III cancer. Maximum cases of stage III were seen in “magic” 
mouthwash and control groups [8 each] followed by chlorhexidine group [7] and 
the least was in salt/sodium bicarbonate group [6] and in stage IV the maximum 
number of cases were seen in salt/sodium bicarbonate group [9] followed by 
chlorhexidine group [8] and the least were in “magic” mouthwash group and the 
control groups [7 each]. Again no statistically significant was observed between 
the groups based on the stage of cancer with p value 0.895. 
 
Thus it was found that there existed no statistically significant 
difference between the patients in four groups, at baseline, based on age, sex 
location of cancer and stage of cancer. 
 
Table – XI: Distribution of patients in the four groups based on mean 
mucositis score at weekly intervals 
The distribution based on the mean mucositis was more at weekly 
intervals, over the 6 week study period, among the four groups were compared. 
Though the mean mucositis score was 0 in all the groups at baseline, after the 1st 
week, maximum increase [0.85] was seen in the control group, while it was less in 
“magic” mouthwash group. 
This trend continued throughout the study period. In the chlorhexidine 
group, the mean mucositis score increased from 0.50 at end of 1st week to 2.42 at 
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the end of 6th week. The mean mucositis score 1st and 6th week interval was 0.53 
to 2.50 in salt / soda group. The increase in “magic” mouthwash group was from 
0.30 to 1.84 and 0.85 to 2.90 in the control group. Overall the mucositis increased 
from 0.54 at the end of first week to 2.42 at the end of sixth week. When ANOVA 
test was used, a statistically significant difference was found between the groups 
at all the weekly intervals. The p value at the end of 1st week was 0.014 and 
0.000 at the end of 2nd, 3rd, 4th, 5th & 6th weeks respectively. 
 
Table – XII: Post hoc analysis of difference in mean mucositis scores between 
different study groups 
A test of repeated measures was used to analyze the difference between the 
groups based on mean mucositis scores, at weekly intervals. Though there existed 
no difference between the groups at baseline, after the 1st week, a statistically 
significant difference was observed between the “magic” mouthwash group and 
control group with a p value of 0.013. At the end of second week, in addition to 
“magic” mouthwash group, chlorhexidine and salt/sodium bicarbonate groups also 
differed from the control group and were statistically significant with p value of 
0.000, 0.001 and 0.021 respectively. However, there existed no significant 
difference between the test groups. Similar results were observed after the 3rd 
week, it was found that there was a significant difference between the test groups 
and the control group with p value of 0.000 for “magic” mouthwash group, 0.000 
for chlorhexidine group and 0.001 for salt/sodium bicarbonate group. But there 
existed no significant difference among the test groups. 
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During the end of 4th week, there was a significant difference compared to 
the test groups (“magic” mouthwash group, chlorhexidine and salt/sodium 
bicarbonate groups) and the control groups with p value of 0.000, 0.000 & 0.002 
respectively. There was also a significant difference observed between “magic” 
mouthwash and salt/sodium bicarbonate group with the p value of 0.016. 5th 
week values showed a significant difference not only between all the test groups 
(“magic” mouthwash group, chlorhexidine and salt/sodium bicarbonate groups) 
and control with p value of 0.000, 0.014 & 0.018 respectively, but also within the 
test groups. Difference in mean mucositis scores between “magic” mouthwash 
and chlorhexidine groups was significantly different with a p value of 0.037, in 
addition to the difference between “magic” mouthwash and salt/soda groups with 
p value of 0.037. Values after 6th week showed a slightly different trend. Though 
there existed a significant difference between “magic” mouthwash and all other 
groups with p value of 0.022 with chlorhexidine group, 0.007 with salt/sodium 
bicarbonate group and 0.000 with the control group, the difference in mean 
mucositis scores among other groups were not statistically significant with p 
value of 0.085 for the chlorhexidine group & 0.252 for the salt/sodium 
bicarbonate group.  
 
Table – XIII: Distribution based on the onset of mucositis between patients in 
the four groups 
             Among the 30 patients who had mucositis onset at 1st week, 12 
belonged to control group while 5 belonged to “magic” mouthwash group, 7 
belonged to the salt/sodium bicarbonate group and 6 belonged to the 
chlorhexidine group. 4 patients in “magic” mouthwash group and 5 in salt/sodium 
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bicarbonate group, 9 in chlorhexidine group and 3 in the control group had onset 
of mucositis at the end of 2nd week and 4 patients in the “magic” mouthwash 
group and 3 in salt/sodium bicarbonate had onset of mucositis after 3 weeks. 1 in 
“magic” mouthwash group had onset of mucositis at 4th and 5th weeks 
respectively. A Chi-square analysis showed a statistically significant difference 
between onset mucositis among the groups [p = 0.005]. 
Analysis was also done comparing the onset of mucositis among the 
test groups and control group and between the tests groups 
 
Table - XIV: Distribution based on the onset of mucositis between patients in 
chlorhexidine and control groups 
80% (12) of patients in control group developed mucositis at the 1st week 
compared to 40% (6) in chlorhexidine group and at the end of 2nd week 9 (60%) 
belonged to chlorhexidine group and 3(20%) belonged to control group. A 
significant difference was found between them (X2 = 7.033, p = 0.008).  
 
Table – XV: Distribution based on the onset of mucositis between patients in 
salt/sodium bicarbonate and control groups 
  The difference observed between salt/sodium bicarbonate and control 
group [p = 0.05] was statistically significant were the onset of mucositis was 
only 46.67% (7) In the salt/sodium bicarbonate group as compared to 80% (12) in 
control group at the end of 1st week and 5 (33.3%) for the salt/sodium bicarbonate 
group and 3(20%) for control group at the end of 2nd week and 3(20%) for the 
salt/sodium bicarbonate at the end of 3rd week.  
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Table – XVI: Distribution based on the onset of mucositis between patients in 
“magic” mouthwash and control groups 
             The onset of mucositis was also statistically significant 
difference between “magic mouthwash” and control group, [p = .010] were only 
33.33% (5) of patients had onset of mucositis at 1st week in “magic” mouthwash 
group as compared to 80% (12) of control group. At the end of 2nd week the onset 
of mucositis in “magic” mouthwash it was 4(26.67%) and 3(20%) in the control 
group. 4 patients in the “magic” mouthwash group had onset of mucositis after 3 
weeks. 1 in “magic” mouthwash group had onset of mucositis at 4th and 5th weeks 
respectively. 
 
Table – XVII: Distribution based on the onset of mucositis between patients 
in chlorhexidine and salt/sodium bicarbonate groups  
A comparison was made between chlorhexidine group and salt/sodium 
bicarbonate group based on the onset of mucositis. At the end of 1st week the 
chlorhexidine group had 6(40%) and 7 (46.67%) in the salt/sodium bicarbonate 
group with onset of mucositis. 9(60%) of patients in the chlorhexidine group had 
onset of mucositis at the end of 2nd week as compared to 5(33.3%) in the 
salt/sodium bicarbonate group. In the third week the salt/sodium bicarbonate 
group had 3(20%) patients with the onset of mucositis. There was no significant 
difference between the two groups. The p value was 0.501 showing that there no 
difference in the onset of mucositis among the two groups 
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Table – XVIII: Distribution based on the onset of mucositis between patients 
in chlorhexidine and “magic” mouthwash groups  
 A comparison was made between the chlorhexidine group and “magic” 
mouthwash group based on the onset of mucositis. It was found that 6(40%) of 
patients had onset of mucositis compared to 5(33.3%) in “magic” mouthwash 
group at the end of 1st week. At the end of 2nd week the onset of mucositis in 
chlorhexidine group was 9(60%) as compared to 4(26.6%) in the “magic” 
mouthwash group. At the end of 3rd week the chlorhexidine group had 4(26.67%) 
of patients had onset of mucositis. 1 (6.67%) patient each had the onset of 
mucositis at the end of 5th and 6th weeks respectively. There was a statistically 
significant difference between the two groups. The p value was 0.05. “Magic” 
mouthwash group had statistically significant lower mucositis scores in this 
prospective study. 
 
Table – XIX: Distribution based on the onset of mucositis between patients in 
salt/sodium bicarbonate groups  
A comparison was made between the salt/sodium bicarbonate group and 
“magic” mouthwash group based on the onset of mucositis. At the end of 1st week 
the salt/sodium bicarbonate group the onset of mucositis was seen in 7(46.67%) as 
compared to 5 (33.3%) in the “magic” mouthwash group. At the end of 2nd week 
in the salt/sodium bicarbonate group 5(33.3%) and 4(26.67%) in the “magic” 
mouthwash had onset of mucositis. At the end of 3rd week 3(20%) in the 
salt/sodium bicarbonate group and 4(26.67%) had onset of mucositis. 1 (6.67%) 
patient each had the onset of mucositis at the end of 5th and 6th weeks respectively. 
There was a statistically significant difference between the two groups. The p 
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value was 0.025. “Magic” mouthwash group had statistically significant lower 
mucositis scores in this prospective study. 
 
Table – XX: Distribution based on the inability of patients to eat solid food in 
four groups 
There was statistically significant difference between the control group 
and the experiment groups in the ability of patients to eat solid food. 
Chlorhexidine and salt/sodium bicarbonate groups (7 each) did not have a 
significant difference between them and “magic” mouthwash (10) was found to 
have a higher degree of the patient’s ability to eat solid food as compared to other 
experiment groups and the least was seen in the control group (3) with the p value 
of 0.001. The relative risk of inability to take solid food was 4.0375 times less in 
“magic” mouthwash group when compared to control group. The Relative risks 
were 2.25 and 2.375, when compared to chlorhexidine and salt/ sodium 
bicarbonate group respectively. 
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Table – I: Distribution based on number of patients who 
completed the study in each group 
 
Group 
 
Number 
Chlorhexidine group 
 
15 (25%) 
Salt/ sodium bicarbonate group 
 
15 (25%) 
“magic” mouth wash group 
 
15 (25%) 
Control group 
 
15 (25%) 
Total 
 
60 (100%) 
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Table – II: Distribution of patients in Chlorhexidine group 
 
Pt. No Age Sex Location of cancer 
1 45 M Tongue 
2 51 M Buccal mucosa 
3 56 M Tongue 
4 69 F Tonsil 
5 63 M Pyriform fossa 
6 56 M Alveolus 
7 49 M Oropharynx 
8 61 M Buccal mucosa 
9 58 M Epiglottis 
10 52 F Nasal cavity 
11 57 M Tongue 
12 49 M Maxillary antrum 
13 61 M Alveolus 
14 72 F Tonsil 
15 55 M Pyriform fossa 
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Table – III: Distribution of patients in salt/sodium  
bicarbonate group 
 
Pt. No Age Sex Location of cancer 
1 48 M Tonsil 
2 71 M Tongue 
3 49 F Posterior pharyngeal wall  
4 64 M Tongue 
5 69 M Buccal mucosa 
6 52 M Epiglottis 
7 51 F Tongue 
8 39 M Pyriform fossa 
9 59 M Larynx 
10 58 M Tongue 
11 64 M Tonsil 
12 54 M Tongue 
13 67 F Vocal cords 
14 48 M Tongue 
15 61 M Buccal mucosa 
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Table – IV: Distribution of patients in “magic” mouthwash group 
 
Pt. No Age Sex Location of cancer 
1 56 M Buccal mucosa 
2 48 F Oropharynx 
3 70 M Epiglottis 
4 52 M Tongue 
5 59 M Hypopharynx 
6 62 M Tongue 
7 49 M Pyriform fossa 
8 58 F Alveolus 
9 41 M Tonsil 
10 61 M Tonsil 
11 69 M Pyriform fossa 
12 71 F Supraglottis 
13 53 M Tonsil 
14 73 M Buccal mucosa 
15 43 F Tongue 
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Table – V: Distribution of patients in Control group 
 
Pt. No Age Sex Location of cancer 
1 61 F Posterior pharyngeal wall  
2 54 M Tongue 
3 59 M Buccal mucosa 
4 71 M Pyriform fossa 
5 65 M Tonsil 
6 67 F Tongue 
7 43 M Tonsil 
8 56 F Epiglottis 
9 60 M Tongue 
10 58 M Maxillary antrum 
11 49 M Buccal mucosa 
12 58 F Tongue 
13 41 F Buccal  mucosa 
14 55 M Alveolus 
15 69 M Supraglottis 
 
 
 
 
 
Tables    
 
 
 65
 
Table – VI: Distribution of patients in the four 
 groups based on sex 
Sex Chlorhexidine 
group 
Salt/ 
Sodium 
bicarbonate 
group 
“magic” 
mouthwash 
group 
Control 
group 
Total 
Male 12 (80%) 12(80%) 11(73.5%) 10(66.66%) 45(75%) 
Female 03(20%) 03(20%) 04(26.6%) 05(33.33%) 15(25%) 
Total 15(100%) 15(100%) 15(100%) 15(100%) 60(100%) 
 
                      p = 0.122 (not significant) 
 
 
Table – VII: Distribution of patients in the four  
groups based on age 
 Chlorhexidine
group 
Salt/Sodium 
bicarbonate 
group 
“magic” 
mouthwash 
group 
Control 
group 
Total 
Mean 
age 
56.933 56.933 57.666 57.733 57.316 
S.D 15.067 14.067 13.334 13.267 14.684 
 
                       p = 0.569 (not significant) 
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Table – VIII: Distribution of patients in the four groups 
 based on the location of cancer 
Location of 
the cancer 
Chlorhexidine 
group 
Salt/ 
Sodium 
bicarbonate 
group 
“magic” 
mouthwash 
group 
Control 
group 
Total 
Alveolus 02 (13.3%) - 01(6.67%) 01(6.67%) 04 
(6.67%) 
Buccal 
mucosa 
02(13.3%) 02(13.3%) 02(13.3%) 03 (20%) 09(15%) 
Epiglottis 01(6.67%) 01(6.67%) 01(6.67%) 01(6.67%) 04(6.67%)
Hypopharynx - - 01(6.67%) - 01(1.67%)
Larynx - 01(6.67%) - - 01(1.67%)
Maxillary 
antrum 
01(6.67%) - - 01(6.67%) 02(3.3%) 
 
Nasal cavity 
 
01(6.67%) 
 
- 
 
- 
 
- 
 
01(1.67%)
Oropharynx 01(6.67%) - 01(6.67%) - 02 (3.3%) 
Postrior 
pharyngeal 
wall 
- 01(6.67%) - 01(6.67%) 02(3.3%) 
Pyriform 
fossa 
02(13.3%) 01(6.67%) 02(13.3%) 01(6.67%) 06 (10%) 
Supraglottis - - 01(6.67%) 01(6.67%) 02(3.3%) 
Tongue 03(20%) 06 (40%) 03(20%) 04 
(26.67%) 
16 
(26.67%) 
Tonsil 02(13.3%) 02(13.3%) 03(20%) 02(13.3%) 09 (15%) 
Vocal cords - 01(6.67%) - - 01(1.67%)
Total 15 15 15 15 60(100%) 
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Table – IX: Distribution of patients in the four groups based on 
cancer of oral cavity or extra-oral region 
Groups Chlorhexidine 
group 
Salt/Sodium 
bicarbonate 
group 
“magic” 
mouthwash 
group 
Control 
group 
Total 
Oral 07 (46.67%) 08(53.33%) 06(40%) 08(53.33%) 29(48.3%) 
Extra 
oral 
08 (53.33%) 07(46.67%) 09(60%) 07(46.67%) 31(51.67%)
Total 15 (100%) 15(100%) 15(100%) 15(100%) 60(100%) 
 
                      p = 0.688 (not significant) 
 
Table – X: Distribution of patients in the four groups  
based on stage of cancer 
 Chlorhexidine 
group 
Salt/Sodium 
bicarbonate 
group 
“magic” 
mouthwash 
group 
Control 
group 
Total 
Stage 
III 
07(46.67%) 06(40%) 08(53.33%) 08(53.33%) 29(48.3%) 
Stage 
IV 
08(53.33%) 09(60%) 07(46.67%) 07(46.67%) 31(51.67%)
Total 15(100%) 15(100%) 15(100%) 15(100%) 60(100%) 
 
                             p = 0.895 (not significant) 
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Table – XI: Distribution of patients in the four groups based on 
mean mucositis score at weekly intervals 
 
Groups  1st  
week 
2nd 
week 
3rd 
week 
4th 
week 
5th 
week 
6th 
week 
Chlorhexidine 
group 
Mean 0.50 1.05 1.40 1.79 2.16 2.42 
SD 0.61 0.22 0.50 0.42 0.60 0.61 
Salt/Sodium 
bicarbonate 
group 
Mean 0.53 1.22 1.50 2.00 2.17 2.50 
SD 0.61 0.65 0.71 0.69 0.62 0.51 
“magic” 
mouthwash 
group 
Mean 0.30 0.74 1.11 1.37 1.58 1.84 
SD 0.47 0.65 0.57 0.68 0.69 0.76 
Control group Mean 0.85 1.80 2.30 2.75 2.80 2.90 
SD 0.37 0.70 0.73 0.64 0.62 0.45 
Total Mean 0.54 1.21 1.58 1.99 2.18 2.42 
SD 0.55 0.69 0.77 0.79 0.76 0.70 
F  3.793 11.442 11.804 17.263 12.112 10.434 
p value  0.014 0.000 0.000 0.000 0.000 0.000 
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Table – XII: Post hoc analysis of difference in mean mucositis 
scores between different study groups 
Dependent 
variable 
Group A Groups B Mean 
difference 
A-B 
SE Significance 
(p) 
 
 
 
 
 
Base line 
Chlorhexidine 
group 
Soda 
“m” m 
Control 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
1.000 
1.000 
1.000 
Salt/Sodium 
bicarbonate 
group 
CHX 
“m” M 
Control 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
1.000 
1.000 
1.000 
“magic” 
mouthwash 
group 
CHX 
Soda 
Control 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
1.000 
1.000 
1.000 
Control group CHX 
Soda 
“m” M 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
1.000 
1.000 
1.000 
 
 
 
 
 
 
 
1st week 
Chlorhexidine 
group 
Soda 
“m” m 
Control 
-0.08 
0.16 
-0.38 
0.173 
0.170 
0.168 
1.000 
1.000 
0.170 
Salt/Sodium 
bicarbonate 
group 
CHX 
“m” M 
Control 
0.08 
0.24 
-0.29 
0.173 
0.173 
0.171 
1.000 
1.000 
0.170 
“magic” 
mouthwash 
group 
CHX 
Soda 
Control 
-0.16 
-0.24 
-0.53 
0.170 
0.173 
0.168 
1.000 
1.000 
0.013 
Control group CHX 
Soda 
“m” M 
0.38 
0.29 
0.53 
0.168 
0.171 
0.168 
0.170 
0.531 
0.013 
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2nd week 
Chlorhexidine 
group 
Soda 
“m” m 
Control 
-0.17 
0.32 
-0.75 
0.194 
0.191 
0.189 
1.000 
0.615 
0.001 
Salt/Sodium 
bicarbonate 
group 
CHX 
“m” M 
Control 
0.17 
0.49 
-0.58 
0.194 
0.194 
0.191 
1.000 
0.087 
0.021 
“magic” 
mouthwash 
group 
CHX 
Soda 
Control 
-0.32 
-0.49 
-1.06* 
0.191 
0.194 
0.189 
0.615 
0.087 
0.000 
Control group CHX 
Soda 
“m” M 
0.75* 
0.58* 
1.06* 
0.189 
0.191 
0.189 
0.001 
0.021 
0.000 
 
 
 
 
 
 
 
 
3rd week 
Chlorhexidine 
group 
Soda 
“m” m 
Control 
-0.08 
0.32 
-0.88* 
0.209 
0.206 
0.204 
1.000 
0.782 
0.000 
Salt/Sodium 
bicarbonate 
group 
CHX 
“m” M 
Control 
0.08 
0.39 
-0.80* 
0.209 
0.209 
0.207 
1.000 
0.379 
0.001 
“magic” 
mouthwash 
group 
CHX 
Soda 
Control 
-0.32 
-0.39 
-1.19* 
0.206 
0.209 
0.204 
0.782 
0.379 
0.000 
Control group CHX 
Soda 
“m” M 
0.88 
0.80 
1.19 
0.204 
0.207 
0.404 
0.000 
0.001 
0.000 
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4th week 
Chlorhexidine 
group 
Soda 
“m” m 
Control 
-0.21 
0.42 
-0.96* 
0.203 
0.200 
0.197 
1.000 
0.232 
0.000 
Salt/Sodium 
bicarbonate 
group 
CHX 
“m” M 
Control 
0.21 
0.63* 
-0.75* 
0.203 
0.203 
0.200 
1.000 
0.016 
0.002 
“magic” 
mouthwash 
group 
CHX 
Soda 
Control 
-0.42 
-0.63 
-1.38* 
0.200 
0.203 
0.197 
0.232 
0.016 
0.002 
Control group CHX 
Soda 
“m” M 
0.96* 
0.75* 
0.75* 
0.197 
0.200 
0.197 
0.000 
0.002 
0.000 
 
 
 
 
 
 
 
 
5th week 
Chlorhexidine 
group 
Soda 
“m” m 
Control 
-0.09 
0.58* 
-0.64* 
0.208 
0.205 
0.203 
1.000 
0.037 
0.014 
Salt/Sodium 
bicarbonate 
group 
CHX 
“m” M 
Control 
0.09 
 0.59* 
-0.80* 
0.208 
0.208 
0.206 
1.000 
0.037 
0.018 
“magic” 
mouthwash 
group 
CHX 
Soda 
Control 
-0.58* 
-0.59* 
-1.19* 
0.205 
0.208 
0.204 
0.037 
0.037 
0.000 
Control group CHX 
Soda 
“m” M 
0.64* 
0.63* 
1.22* 
0.203 
0.206 
0.203 
0.014 
0.018 
0.000 
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6th week 
Chlorhexidine 
group 
Soda 
“m” m 
Control 
-0.08 
0.58* 
-0.48 
0.197 
0.193 
0.190 
1.000 
0.022 
0.085 
Salt/Sodium 
bicarbonate 
group 
CHX 
“m” M 
Control 
0.08 
 0.66* 
-0.40* 
0.196 
0.196 
0.193 
1.000 
0.007 
0.252 
“magic” 
mouthwash 
group 
CHX 
Soda 
Control 
-0.58* 
-0.66 
-1.06* 
0.193 
0.196 
0.190 
0.022 
0.007 
0.000 
Control group CHX 
Soda 
“m” M 
0.48 
0.40 
1.06* 
0.190 
0.193 
0.190 
0.085 
0.252 
0.000 
 
                          ‘*’ = p value is statistically significant 
                          CHX = Chlorhexidine group 
                          Soda = Salt/Sodium bicarbonate group 
                          “m” M = “magic” Mouthwash group 
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Table – XIII: Distribution based on the onset of mucositis between 
patients in the four groups 
Weeks Chlorhexidine 
group 
Salt/Sodium 
bicarbonate 
group 
“magic” 
mouthwash 
group 
Control 
group 
Total 
1 6 (40%) 7 (46.67%) 5(33.3%) 12(80%) 30(50%) 
2 9 (60%) 5(33.3%) 4(26.67%) 3(20%) 17(28.3%) 
3  3(20%) 4(26.67%)  11(18.3%) 
4   1(26.67%)  1(1.67%) 
5   1(26.67%)  1(1.67%) 
Total 15(100%) 15(100%) 15(100%) 15(100%) 60 (100%) 
 
                                 p = 0.0005 (highly significant) 
 
Table - XIV: Distribution based on the onset of mucositis between 
patients in chlorhexidine and control groups 
Week Chlorhexidine 
group 
Control group Total 
1 6(40%) 12(80%) 18(60%) 
2 9(60%) 3(20%) 12(40%) 
Total 15(100%) 15(100%) 30(100%) 
 
                                       p = 0.008 (highly significant)  
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Table – XV: Distribution based on the onset of mucositis between 
patients in salt/sodium bicarbonate and control groups 
Week Salt/Sodium 
bicarbonate group
Control group Total 
1 7(46.67%) 12(80%) 19(63.33%) 
2 5(33.3%) 3(20%) 08(20.67%) 
3 3(20%)  03(10%) 
Total 15(100%) 15(100%) 30(100%) 
 
                                        p = 0.05 (significant) 
 
Table – XVI: Distribution based on the onset of mucositis between 
patients in “magic” mouthwash and control groups 
Week “magic” 
mouthwash group 
Control group Total 
1 5(33.3%) 12 (80%) 17 (56.67%) 
2 4(26.67%) 3(20%) 07(23.3%) 
3 4(26.67%)  04(13.3%) 
4 1(6.67%)  01(3.3%) 
5 1(6.67%)  01(3.3%) 
Total 15(100%) 15 (100%) 30(100%) 
 
                                          p = 0.010 (highly significant) 
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Table – XVII: Distribution based on the onset of mucositis between 
patients in chlorhexidine and salt/sodium bicarbonate groups 
Week Chlorhexidine 
group 
Salt/Sodium 
bicarbonate 
group 
Total 
1 6(40%) 7(46.67%) 19(63.3%) 
2 9(60%) 5(33.3%) 08(20.67%) 
3 - 3(20%) 03(10%) 
Total 15(100%) 15(100%) 30(100%) 
                                       p = 0.501(not significant) 
  
Table – XVIII: Distribution based on the onset of mucositis 
between patients in chlorhexidine and “magic” mouthwash groups 
 
Week Chlorhexidine 
group 
“magic” 
mouthwash 
group 
Total 
1 6(40%) 5(33.3%) 17(56.67%) 
2 9(60%) 4(26.67%) 07(23.3%) 
3 - 4(26.67%) 04(13.3%) 
4 - 1(6.67%) 01(3.3%) 
5 - 1(6.67%) 01(3.3%) 
Total 15(100%) 15(100%) 30(100%) 
                                             p = 0.05 (significant)  
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Table – XIX: Distribution based on the onset of mucositis between 
patients in salt/sodium bicarbonate and “magic” mouthwash groups 
Week Salt/sodium 
bicarbonate 
group 
“magic” 
mouthwash group
Total 
1 7(46.67%) 5(33.3%) 17(56.67%) 
2 5(33.3%) 4(26.67%) 07(23.33%) 
3 3(20%) 4(26.67%) 04(13.33%) 
4 - 1(6.67%) 01(3.33%) 
5 - 1(6.67%) 01(3.33%) 
Total 15(100%) 15(100%) 30(100%) 
                                            p = 0.025 (significant) 
 
Table – XX: Distribution based on the inability of patients            
to eat solid food in four groups 
 Chlorhexidine 
group 
Salt/sodium 
bicarbonate 
group 
“magic” 
mouthwash 
group 
Control 
group 
Total 
Inability 
to eat 
solid 
food 
08(53.3%) 08(53.3%) 05(33.3%) 12(80%) 33(55%) 
Ability 
to eat 
solid 
food 
07(46.67%) 07(46.67%) 10(66.67%) 03(20%) 27(45%) 
Total 15(100%) 15(100%) 15(100%) 15(100%) 60(100%) 
 
                                          p value of 0.001 (very highly significant) 
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Graph – I: Distribution based on number of patients who completed 
the study in each group 
 
 
 
 
 
 
Graph – II: Distribution of patients in the four groups based on sex 
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Graph - III: Distribution of patients in the four groups based on age 
 
 
 
Graph – IV: Distribution of patients in the four groups based 
on the location of cancer 
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Graph – V: Distribution of patients in the four groups based on 
cancer of oral cavity or extra-oral region 
 
 
 
Graph – VI: Distribution of patients in the four groups based 
on stage of cancer 
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Graph – VII: Distribution of patients in the four groups based on 
mean mucositis score at weekly intervals 
 
 
 
 
Graph – VIII: Distribution based on the onset of mucositis between 
patients in the four groups 
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Graph - IX: Distribution based on the onset of mucositis between 
patients in chlorhexidine and control groups 
 
 
 
Graph – X: Distribution based on the onset of mucositis between 
patients in salt/sodium bicarbonate and control groups 
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Graph – XI: Distribution based on the onset of mucositis between 
patients in “magic” mouthwash and control groups 
 
 
 
Graph – XII: Distribution based on the onset of mucositis between 
patients in chlorhexidine and salt/sodium bicarbonate groups 
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Graph – XIII: Distribution based on the onset of mucositis between 
patients in chlorhexidine and “magic” mouthwash groups 
 
 
Graph – XIV: Distribution based on the onset of mucositis between 
patients in salt/sodium bicarbonate and “magic” mouthwash groups 
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Graph – XV: Distribution based on the inability of patients to eat 
solid food in four groups 
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Head and neck cancers rank among the top three malignancies in our 
country for both males and females. The wide spread use of tobacco in various 
forms due to our cultural habits coupled with lack of awareness of its carcinogenic 
effects are mainly responsible for their prevalence. Ignorance of the early 
symptoms together with the lack of proper diagnostic and treatment facilities at 
the gross root level lead to presentation of patients to cancer hospitals in advanced 
disease stages in our country. 
 
Radiation/chemotherapy (combination therapy) is a unique modality of 
cancer treatment which can be used to cure and palliate cancer. Here high energy 
ionizing radiation, is made to pass through cancerous tissues, leading to ionization 
of the DNA (Deoxyribonucleic acid) of the later; either directly or indirectly 
(through free radical formation) causing reproductive death in the cancerous cells. 
Thus when the damaged cancerous cell attempts to divide it suffers cell death, 
leading to tumor regression which occurs over a period of several days i.e. up to 
six weeks after the completion of radiation. It has been estimated that nearly 70% 
of all cancers need some form of radiotherapy to complete their treatment. 
 
One of the most important applications of combination therapy is in the 
treatment of head and neck cancers where combination therapy is favoured over 
surgery due to the functional loss associated with later. Radiation, differs from 
other forms of therapy in that, there are effective antidotes for side effects induced 
by allopathic drugs while radiation induced side effects are usually persistent, 
problematic, debilitating and difficult to relieve permanently. Hence preventing 
these side effects is of immense importance to ensure the success of treatment. 
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Radiation induced side effects result from the damage caused by the 
radiation to the normal tissues which lie in the path of the radiation beam. The 
effects of  radiation on the normal tissues varies depending on the tissue type and 
its radio sensitivity, radiation dose (total dose and dose per radiation fraction), 
volume of normal tissue irradiated, radiation technique and equipment used and 
combination of other treatment modalities such as chemotherapy. Based on their 
severity radiation induced toxicity are graded as reactions or toxicity. While low 
grade radiation induced changes are called reactions whereas severe forms of the 
same injury are referred to as toxicity. 
 
The aim of radiotherapy treatment planning is to maximize the dose 
delivery to the tumor without exceeding the normal tissue tolerance for 
radiotherapy. However in spite of the utmost care in preventing normal tissue 
reactions, one can only minimize normal tissue reactions and cannot prevent them 
totally. Hence emphasis in research work on radiation science is centered not only 
on identifying methods to improve the precision of dose delivery but also in 
identifying newer therapeutic modalities to cure and minimize the morbidity of 
radiation induced toxicity. 
 
  Radiation or chemotherapy induced mucositis is an important and 
inseparable side effect of head and neck radiation. Mucositis usually begins in the 
third week of radiation or chemotherapy and progressively increases in severity 
with continued treatment. Randomized controlled studies have shown that any 
disruption in the treatment leads to tumor repopulation which negatively affects 
tumor control. Attempts to minimize tumor repopulation such as accelerated 
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fractionation, Continuous hyper fractionated accelerated radiotherapy have 
increased local control at the cost of increased acute toxicity manifesting primarily 
as severe mucositis. The same holds good for concurrent chemo-radiation as well. 
Thus at every step in the treatment of head and neck malignancies the occurrence 
and severity of radiation induced mucositis acts as a rate limiting step, which has 
to be overcome to increase local control and treatment efficacy. 
 
Currently there is no worldwide concurrence on the treatment protocol to 
be followed to manage radiation induced mucositis. While the broad principles of 
treatment such as maintenance of oral hygiene use of antibiotics and analgesics 
have remained the same for the past several years, oncological research is yet to 
identify the single drug of choice to treat / cure radiation induced mucositis.  
 
The present study was done to find out the effect of three alcohol-free 
mouthwashes on chemo radiation – induced oral mucositis in patients with head 
and neck malignancies. It is predictable that chemo radiotherapy for head and 
neck malignancies will result in oral mucositis when the oral mucosa is included 
in the treatment field. The study of oral mucositis associated with chemo 
radiotherapy can serve as a model for mucosal disruptions resulting from other 
causes, when symptomatic management is studied. Therefore, the findings of this 
trial may have implications in management of mucositis as a result of causes that 
may include radiotherapy, chemotherapy, trauma, infection and oral dermatosea12. 
 
Increased risk of oral cancer among users of alcohol – containing 
mouthwash was observed several years ago. In one hospital-based investigation 
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conducted by the American Health Foundation, a significant 2.8-fold excess risk 
was found among women who used mouthwash daily, with the odds ratio [OR] 
increasing to 3.6 among non smokers and non drinkers, while the odds ratio 
among men was 1.143. 
 
In a study by Bolt WJ et al2 investigated the high risk of oral cancer 
among women involving 206 cancer patients and 352 controls. Odds ratio 
associated with alcohol-containing mouthwash use was 1.1 overall, but 1.9 among 
those abstaining from tobacco use. 
 
Weaver A et al40, in their study observed that among 11 oral cancer 
patients who used neither tobacco nor alcohol, 10 were long-term alcohol-
containing mouthwash users. 
 
Mashberg A et al 23 in their study showed that the use of mouthwash 
containing alcohol have little association with oral and pharyngeal cancer. The 
adjusted odds ratio of 0.94 indicated that the risk of cancer was actually slightly 
less for mouthwash users than for non-users. 
 
However Winn MD et al 42, in his interview with 866 patients with cancer 
of the oral cavity and pharynx, and 1249 controls of similar age and sex, from the 
general population in four areas of the United States, revealed increased risks 
associated with the regular use of alcohol-containing mouthwash. Risk of oral 
cancer was elevated by 40% among males and 60% among females, after 
adjusting for tobacco and alcohol consumption. 
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Whether mouthwash use per se, or factors related to mouthwash use or its 
reporting, accounts for the association with oral cancer, is not clear 42. A causal 
interpretation seems biologically plausible because mouthwash contains an oral 
carcinogen, alcohol, and drinking alcoholic beverages is a well-recognized cause 
of oral cancer 42. Alcohol is generally used in mouthwashes to enhance flavor 
impact and also solubilize the flavor and some active ingredients, and also provide 
some preservative power.  
           
Mouthwashes often contain coloring, flavoring or sweetening agents, but 
the association with brands having a high alcohol-content suggests that alcohol 
may be responsible for carcinogenesis, at least in part. Since pure alcohol [i.e., 
ethanol] has not been shown to be carcinogenic in laboratory animals, the 
mechanism by which alcoholic beverages induce oral cancer is unknown, but 
probably involves topical exposure, perhaps with a solvent action that enhances 
penetration of tobacco and other carcinogens. Oral swishing with a mouthwash 
containing 25% ethanol might provide a local mucosal tissue exposure similar to 
drinking a 100 proof (50% ethanol) alcoholic beverage diluted with equal parts of 
alcohol or other mixers, although quantitative comparisons are not available 42. 
 
Recent studies 4 have shown no significant difference between alcoholic 
and alcohol-free formulations of chlorhexidine in reducing plaque and papillary 
bleeding. Hence, in the present study, the effects of three alcohol-free 
mouthwashes were assessed.  
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Chlorhexidine gluconate is the most commonly used mouthwash in 
dentistry. It is an antimicrobial agent that appears to be effective in controlling 
early periodontal infections. It reduces the oral micro flora, promote re-
epithelization of soft tissue lesions, normalize the pH of oral fluids, has an 
acceptable taste, and it is nontoxic.  
 
Saline solution is thought to aid in formation of granulation tissue and to 
promote healing. Saline solution mouthwashes are safe and economic and have 
been used in cancer population. Normal saline gargles cleanse the wounds, reduce 
swelling and can decrease pain. Sodium bicarbonate has also been used as a 
cleansing agent because of its ability to dissolve mucus and loosen debris. The 
combination of salt and sodium bicarbonate raises oral pH and prevents 
overgrowth of aciduric bacteria. 
 
Recent reports suggested that the ‘magic’ mouthwash which consisted of 
“mixtures” aimed at producing analgesia or anesthesia and coating the inflamed 
and painful oral mucosa. There is not much evidence existing to support the 
efficacy of this mixture in the treatment of mucositis but this combination could 
be a material of choice for treating mucositis9. 
 
Thus, the above mentioned three mouthwashes were chosen to assess their 
efficacy in reducing chemo-radiotherapy induced mucositis. 
 
The study group consisted of a total number of 60 patients; the patients 
were randomly and equally divided in four groups of 15 each. The four groups 
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were (i) chlorhexidine group, (ii) salt/sodium bicarbonate group, (iii) “magic” 
mouthwash group and (iv) control group.  
 
The mean age of patients in chlorhexidine and salt/sodium bicarbonate 
group were 56.93 years each and the mean age of patients in “magic” mouthwash 
group was 57.66 years and 57.73 years was the mean age of patients in control 
group. It was found that there existed no statistically significant difference 
between the ages of patients in four groups. 
 
In all the groups, the number of males exceeded the females. 80% of the 
patients were males in both chlorhexidine and salt/sodium bicarbonate group 
followed by 73.3% in the “magic” mouthwash group and the control group had 
the minimum of 66.6%. There existed no statistically significant difference 
between the groups based on sex distribution. 
 
Radiation field size is always more for patients with cancer of oral cavity 
than those with cancer of extra-oral region. The above difference can be explained 
by the fact that radiation damage is site-specific; toxicity is localized to irradiated 
tissue volume. Hence toxicities of radiotherapy are always severe for patients with 
cancer of oral cavity, than the latter. Based on this report four groups were divided 
into those cancers of oral cavity and those having cancer of extra-oral region. 
Cancer of alveolus, buccal mucosa and tongue were considered as cancer of oral 
cavity, the rest were considered as cancer of extra-oral region. Cancer of extra-
oral region was all the groups and accounted for 31(51.67%) cases, among the 
total completed cases and 29(48.3%) patients who had cancer of oral cavity. No 
 
Discussion   
 
 
 92
statistically significant difference was found between the groups based on the 
location of cancer. 
 
The patients were also grouped based on the staging of cancer, according 
to TNM classification. Among the total patients, 51.67% had stage IV cancer and 
48.3% had stage III cancer. Again no statistically significant was observed 
between the groups based on the stage of cancer. 
 
Thus, it was found that there existed no statistically significant difference 
between the patients in four groups, at baseline, based on age, sex, location of 
cancer and stage of cancer.            
 
The present study demonstrates that rinsing with “magic” mouthwash 
reduced the incidence and severity of radiation-induced oral mucositis, when 
compared to chlorhexidine, salt/soda and placebo mouthwash. Dodd et al9 in their 
studies had shown that rinsing with salt/soda, chlorhexidine and “magic 
mouthwash produced similar results and reduced the incidence, severity and 
duration of chemotherapy-induced oral mucositis. 
 
  Oral mucositis during radiation therapy is caused by various factors, 
while pain and inability to eat are the common complaints of patients with 
mucositis. Therefore, analgesic or anesthetic agents may decrease the severity of 
pain and improve the ability to eat31. For this purpose, “magic” mouthwash seems 
to be very useful. “Magic” mouthwash forms a coating over the inflamed and 
painful oral mucosa. The 3 most common ingredients in these mixtures are 
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viscous lidocaine solution, diphenhydramine hydrochloride and aluminium 
hydroxide suspension. However, because the use of these agents is common in 
clinical practice, this combination could be a material of choice for treating 
mucositis9. 
 
Another well-known economic antiseptic agent, chlorhexidine was not 
found to be as effective as “magic” mouthwash in the present study. In their 
studies, Spijkervet FKL et al32 and Ferretti GA et al15 observed little or no 
reduction of mucositis in patients receiving high-dose head and neck radiotherapy 
when chlorhexidine was used as mouthwash. Foote RL et al15, in his study, 
showed slightly more stomatitis and side effects in the chlorhexidine patients, thus 
ruling out the possibility that chlorhexidine can lower the average daily mucositis 
score. However the placebo mouthwash used in this study did not contain any 
alcohol while chlorhexidine had a 12% alcohol vehicle. 
 
Epstein JB et al12 demonstrated little effect on lactobacillus count in 
patients receiving cancer radiotherapy after use of chlorhexidine rinse. 
 
The lack of effect of chlorhexidine mouthwash in patients undergoing 
radiotherapy may be explained by the observation that the chlorhexidine 
molecule, a divalent cation, probably does not bind directly to epithelial tissues 
but rather to negatively charged salivary mucins or glycoproteins. In-vitro 
evidence further supports the concept that salivary glycoproteins are necessary co-
factors for mucosal cell protection by chlorhexidine. But, severe persistent 
xerostomia develops in patients receiving high-dose radiation therapy rather 
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quickly [within 14 to 21 days] after the initiation of radiation therapy, thus 
depriving oral epithelial tissues of their usual coating of salivary fluids, and 
diminishing the effect of chlorhexidine in these patients14. However Toljanic JA 
et a137, in his study on six subjects, showed that 0.12% chlorhexidine was retained 
in the oral cavity for atleast 4 hours after an initial rinsing, and that the property of 
substantivity remains active, in spite of radiation – induced changes in the oral 
cavity and salivary glands. 
 
Samaranayake LP et al29 suggested use of chlorhexidine rinse in patients 
undergoing post-operative radiotherapy for squamous carcinoma of oral cavity 
than Benzylamine mouthwash as former caused less oral discomfort. 
 
In the present study, the effect of salt/soda mouthwash was also not as 
effective as “magic” mouthwash, though it was more effective than control group. 
Feber T14, in his study, concluded that management of mucositis in oral 
irradiation was better with saline than hydrogen peroxide rinses. Dodd MJ et al10 
suggested than since there is no significant difference in efficacy between 
micronized sucrolfate and salt and soda, use of the less costly salt and soda is 
prudent and cost-effective. However Carl W and Emrich LS5 showed that grade-
3 mucositis developed more in patients who used conventional oral care with 5% 
sodium bicarbonate, saline and 3% hydrogen peroxide. 
 
Studies have shown that frequency of mucositis was highest in patients 
treated with radiotherapy, affecting 100% of patient’s overall38. In the present 
study also, all the patients (60 patients) who completed the trial developed some 
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degree of mucositis. The onset, intensity and duration of mucositis vary with the 
individual but most often start in the second week of therapy, or after a dose of 
about 2000 cGy. More than 50% patients (30), in the present trial developed 
mucositis in the first week after radiotherapy, while another 17 developed 
mucositis after 2 weeks of therapy. The range of onset of mucositis was 1-2 weeks 
for chlorhexidine and control group, 1-5 weeks for “magic” mouthwash and 1-3 
weeks for salt/ sodium bicarbonate group. The onset of mucositis was 
significantly slow in “magic” mouthwash group when compared to control group 
and the other test groups. 
 
The ability to take solid food [score 3 and above] was calculated between 
“magic” mouthwash and other groups. Among the four groups, there was 
statistically significant difference between the control group and the experiment 
groups in the ability of patients to eat solid food. Chlorhexidine and salt/sodium 
bicarbonate groups did not have a significant difference between them and 
“magic” mouthwash was found to have a higher degree of the patient’s ability to 
eat solid food as compared to other experiment groups. The relative risk of 
inability to take solid food was four times less in “magic” mouthwash group when 
compared to control group. The relative risks were 2 each, when compared to 
chlorhexidine and salt/ sodium bicarbonate group respectively. 
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To summarize,                          
  Just as every action has an equal and opposite reaction, every drug has its 
own beneficial as well as adverse effects. Radiotherapy like chemotherapy can be 
compared to a drug which cures cancer, but with its side effects causes debilitating 
effects on organs. One of the most important and debilitating effects of radiation 
on normal tissues, which is potentially curable, is radiation induced mucositis. It is 
seen as an inevitable accompaniment to external beam radiotherapy and mucositis 
is a painful condition which is debilitating physically and mentally. 
 
  The current randomized controlled study evaluated the effectiveness of 3 
commonly used mouthwashes to treat chemo radiotherapy induced mucositis. The 
study was conducted in the department of Oral Medicine and Radiology, Ragas 
Dental College, Uthandi, Chennai at Dr. Rai memorial medical and cancer centre 
and cancer shelter, Chennai. 
 
      Of the total 88 patients who reported to Dr. Rai memorial medical and 
cancer centre and cancer shelter for treatment of head and neck malignancies, 60 
patients, who fulfilled the inclusion criteria, participated in this trial and were 
Randomly allocated into four groups. 
 
  Cobalt 60 is used as the radioactive source that emits gamma rays at an 
average energy level of 1.2 MeV. In addition, moulds are made for all head and 
neck malignancy patients undergoing radiotherapy for immobilization of their 
head during radiation. These patients received external bilateral irradiation, 2 Gys 
daily, for a total dose of 60 Gys: the doses given five days a week over a period of 
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6 weeks. The irradiation portals were such that the major salivary glands (parotid 
and submandibular) were included. Radical resection or de bulking of the primary 
tumor often preceded the course of irradiation.       
                    
           Along with radiotherapy, anticancer drugs such as 100mg/m2 of cisplatin 
was given on the first day followed by the second dose on the twenty second day 
and third on the forty third day and 600mg/m2 of 5-fluorouracil was administered 
continuously for first five days on weeks one and six respectively. The 
mouthwashes were numbered randomly from 1 to 60 by the mouth wash 
manufacture. The mouthwashes assessed were 1) 0:12% chlorhexidine, 2) Salt / 
sodium bicarbonate, 3) “magic” mouthwash & 4) plain water [control]. 
 
  Mucositis was assessed using the World Health Organization grading of 
Mucositis, as it is the most common scale used to assess Mucositis severity. 
Assessment of Mucositis was done at base line, and after each week of 
chemoradiation therapy for 6 weeks. Examinations of patients were done under 
standard illumination and relevant data (name, age, sex, location of cancer, stage 
of cancer and details regarding the ability to eat solid food) were collected. 
 
The mean ages of patients were estimated and it was found that there 
existed no statistically significant difference (p = 0.569) between the ages of 
patients in four groups. On evaluating the sex distribution it was found that there 
existed no statistically significant difference (p = 0.122) between the groups based 
on sex distribution. Location of the cancer were classified as extra oral and intra 
oral and it was found that there existed no statistically significant difference (p = 
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0.688) between the groups based on the location of cancer. The patients were also 
grouped based on the staging of cancer, according to TNM classification. Again 
no statistically significance  (p = 0.895) was observed between the groups based 
on the stage of cancer. 
 
 Thus, it was found that there existed no statistically significant difference 
between the patients in four groups, at baseline, based on age, sex, location of 
cancer and stage of cancer. 
 
 Patients were assessed for the mean mucositis scores at weekly intervals 
and the present study demonstrated that rinsing with “magic” mouthwash reduced 
the incidence and severity of radiation-induced oral mucositis, when compared to 
chlorhexidine, salt/soda and placebo mouthwash. The onset of mucositis was also 
estimated and it was found that the onset of mucositis in control group and the 
chlorhexidine group is by the end of second week. The salt/sodium bicarbonate 
group extended till the third week and the “magic” mouthwash group till the fifth 
week. The onset of mucositis was significantly slow in “magic” mouthwash group 
when compared to control group and the other test groups (p = 0.0005). 
 
The ability to eat solid food was compared among the four groups. It was 
found that there was a statistically significant difference (p = 0.001) between the 
control group and the experiment groups in the ability of patients to eat solid food. 
Chlorhexidine and salt/sodium bicarbonate groups did not have a significant 
difference between them, and “magic” mouthwash group was found to have a 
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higher degree of the patient’s ability to eat solid food as compared to other 
experiment groups and the least was seen in the control group. 
       
The conclusions of the present study are: 
1. The onset of mucositis was slow in test groups (chlorhexidine, 
salt/sodium bicarbonate & “magic” mouthwash) as compared to the 
control group. “Magic” mouthwash was found have delay in onset as 
compared to other test groups. 
2. The ability to eat solid food was high in “magic” mouthwash group 
compared to all other groups (chlorhexidine, salt/sodium bicarbonate & 
control groups). 
3. The test groups were found to reduce the severity of mucositis compared 
to control group. “Magic” mouthwash was found to decrease the severity 
of mucositis compared to other test groups and the control group. 
 
                            In conclusion, currently, there is no established prophylactic 
method to decrease chemo radiation – induced oral mucositis. But for preparing 
the patients by eliminating the foci of infection, proper dental and oral hygiene 
maintenance and appropriate use of radiation therapy stents and blocks appear to 
be the best standard approach for these patients followed by a “magic” mouthwash 
gargling could help the patient to bring down the oral mucositis from 2nd to 6th 
week with effective healing of the oral mucosa enabling the patient to eat solid 
food. The study could be conducted in a larger population undergoing chemo 
radiation which can bring more information to relive the sufferings from chemo 
radiation induced oral mucositis. 
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commonly used mouthwashes to treat chemo radiotherapy induced mucositis. The 
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  Cobalt 60 is used as the radioactive source that emits gamma rays at an 
average energy level of 1.2 MeV. In addition, moulds are made for all head and 
neck malignancy patients undergoing radiotherapy for immobilization of their 
head during radiation. These patients received external bilateral irradiation, 2 Gys 
daily, for a total dose of 60 Gys: the doses given five days a week over a period of 
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6 weeks. The irradiation portals were such that the major salivary glands (parotid 
and submandibular) were included. Radical resection or de bulking of the primary 
tumor often preceded the course of irradiation.       
           Along with radiotherapy, anticancer drugs such as 100mg/m2 of cisplatin 
was given on the first day followed by the second dose on the twenty second day 
and third on the forty third day and 600mg/m2 of 5-fluorouracil was administered 
continuously for first five days on weeks one and six respectively. The 
mouthwashes were numbered randomly from 1 to 60 by the mouth wash 
manufacture. The mouthwashes assessed were 1) 0:12% chlorhexidine, 2) Salt / 
sodium bicarbonate, 3) “magic” mouthwash & 4) plain water [control]. 
  Mucositis was assessed using the World Health Organization grading of 
Mucositis, as it is the most common scale used to assess Mucositis severity. 
Assessment of Mucositis was done at base line, and after each week of 
chemoradiation therapy for 6 weeks. Examinations of patients were done under 
standard illumination and relevant data (name, age, sex, location of cancer, stage 
of cancer and details regarding the ability to eat solid food) were collected. 
The mean ages of patients were estimated and it was found that there 
existed no statistically significant difference (p = 0.569) between the ages of 
patients in four groups. On evaluating the sex distribution it was found that there 
existed no statistically significant difference (p = 0.122) between the groups based 
on sex distribution. Location of the cancer were classified as extra oral and intra 
oral and it was found that there existed no statistically significant difference (p = 
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0.688) between the groups based on the location of cancer. The patients were also 
grouped based on the staging of cancer, according to TNM classification. Again 
no statistically significance  (p = 0.895) was observed between the groups based 
on the stage of cancer. 
 Thus, it was found that there existed no statistically significant difference 
between the patients in four groups, at baseline, based on age, sex, location of 
cancer and stage of cancer. 
 Patients were assessed for the mean mucositis scores at weekly intervals 
and the present study demonstrated that rinsing with “magic” mouthwash reduced 
the incidence and severity of radiation-induced oral mucositis, when compared to 
chlorhexidine, salt/soda and placebo mouthwash. The onset of mucositis was also 
estimated and it was found that the onset of mucositis in control group and the 
chlorhexidine group is by the end of second week. The salt/sodium bicarbonate 
group extended till the third week and the “magic” mouthwash group till the fifth 
week. The onset of mucositis was significantly slow in “magic” mouthwash group 
when compared to control group and the other test groups (p = 0.0005).
The ability to eat solid food was compared among the four groups. It was 
found that there was a statistically significant difference (p = 0.001) between the 
control group and the experiment groups in the ability of patients to eat solid food. 
Chlorhexidine and salt/sodium bicarbonate groups did not have a significant 
difference between them, and “magic” mouthwash group was found to have a 
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experiment groups and the least was seen in the control group. 
The conclusions of the present study are:
1. The onset of mucositis was slow in test groups (chlorhexidine, 
salt/sodium bicarbonate & “magic” mouthwash) as compared to the 
control group. “Magic” mouthwash was found have delay in onset as 
compared to other test groups. 
2. The ability to eat solid food was high in “magic” mouthwash group 
compared to all other groups (chlorhexidine, salt/sodium bicarbonate & 
control groups). 
3. The test groups were found to reduce the severity of mucositis compared 
to control group. “Magic” mouthwash was found to decrease the severity 
of mucositis compared to other test groups and the control group. 
                            In conclusion, currently, there is no established prophylactic 
method to decrease chemo radiation – induced oral mucositis. But for preparing 
the patients by eliminating the foci of infection, proper dental and oral hygiene 
maintenance and appropriate use of radiation therapy stents and blocks appear to 
be the best standard approach for these patients followed by a “magic” mouthwash 
gargling could help the patient to bring down the oral mucositis from 2nd to 6th
week with effective healing of the oral mucosa enabling the patient to eat solid 
food. The study could be conducted in a larger population undergoing chemo 
radiation which can bring more information to relive the sufferings from chemo 
radiation induced oral mucositis. 
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RAGAS DENTAL COLLEGE & HOSPITAL 
2/102, EAST COAST ROAD, Uthandi, Chennai – 600119 
DEPARTMENT OF ORAL MEDICINE & RADIOLOGY 
PROFORMA FOR STUDY TO COMPARE THE EFFICACY & 
EFFECTIVENESS OF THREE COMMONLY USED MOUTHWASHES 
TO TREAT CHEMORADIOTHERAPY INDUCED MUCOSITIS 
                                                                                                                         Date: 
S.No: 
Op.No:        
Name:                                                                                            Age/Sex: 
Address: 
 
Phone number: 
Occupation: 
Monthly income: 
Chief complaint: 
History of presenting illness: 
Past medical history: 
Past surgical history: 
Past dental history: 
Personal habits: 
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- Chewing habits (Duration/ Frequency) 
- Smoking  (Duration / Frequency) 
- Alcohol consumption (Duration / Frequency)                                                
                                                             
General examination: 
- Height / Weight:                   / 
Local examination: 
- Extra oral (Examination of lymph nodes) 
                                                         -  Number of nodes 
                      -  Consistency 
                      -  Warmth 
                      -  Tenderness 
                      -  Mobile / Fixed 
 
- Intra oral 
            Gingival 
Labial & buccal mucosa 
Alveolar mucosa 
Tongue 
Palatal mucosa 
Floor of the mouth 
Teeth 
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Diagnosis: 
TNM stage:      Stage I 
                          Stage II 
                          Stage III 
                          Stage IV 
 
Chemotherapy prescription: 
Radiotherapy prescription:                      Gy in             # in             weeks 
Radiotherapy delivered with:      Telecobalt / Linac 
Mouthwash:          bottle number -  
Any side effect perceived: 
Protocol completed:              yes / no 
Subjective symptoms:  Pain ( I / II / III / IV / V / VI weeks)  
                                       Dysphagia (I / II / III / IV / V / VI weeks) 
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WHO index for grading chemo radiation- induced oral mucositis 
 
 
 
 
 
 Baseline 1st 
week 
2nd 
week 
3rd 
week 
4th 
week 
5th 
week 
6th 
week 
Buccal 
Mucosa (R) 
       
Buccal 
Mucosa (L) 
       
Soft Palate        
Hard Palate        
Dorsum of 
Tongue 
       
Lateral 
Border of 
tongue(R) 
       
Lateral 
Border of 
tongue(L) 
       
Floor of 
Mouth 
       
Score        
 
Annexure    
 
 
 110
CONSENT FORM 
                           I, ___________________________________ , the undersigned 
hereby give my consent for participation as a subject in the study titled “TO 
COMPARE THE EFFICACY AND EFFECIENCY OF THREE COMMONLY 
USED MOUTHWASHES TO TREAT CHEMORADIOTHERAPY INDUCED 
MUCOSITIS” conducted by Dr. P. Jagathesh under the guidance of Capt.          
Dr. S. Elangovan. Professor, Dept. of Oral Medicine & Radiology, Ragas Dental 
College & Hospital, Chennai. 
                          I have been counseled about this study and as a part of this study 
protocol I unconditionally and freely give my consent to participate in this study. 
Date: 
Place:                                                                                       Signature 
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Master Chart 
S.N
o 
Age  Sex  Group Location Extra/Intra 
oral 
Stage Onset of 
mucositis 
Ability to eat 
solid food 
1 45 M CHX Tongue Intra oral  III  1st week  No 
2 51 M CHX Buccal mucosa Intra oral  III  2nd week  Yes 
3 56 M CHX Tongue Intra oral  III  1st week  No 
4 69 F CHX Tonsil Extra oral  IV  2nd week  Yes 
5 63 M CHX Pyriform fossa Extra oral  IV  1st week  No 
6 56 M CHX Alveolus Intra oral  III  2nd week  Yes 
7 49 M CHX Oropharynx Extra oral  IV  2nd week  Yes 
8 61 M CHX Buccal mucosa Intra oral  IV  1st week  No 
9 58 M CHX Epiglottis Extra oral  III  2nd week  Yes 
10 52 F CHX Nasal cavity Extra oral  IV  1st week  No 
11 57 M CHX Tongue Intra oral  IV  1st week  No 
12 49 M CHX Maxillary 
antrum 
Extra oral  III  2nd week  Yes 
13 61 M CHX Alveolus Intra oral  IV  2nd week  Yes 
14 72 F CHX Tonsil Extra oral  IV  2nd week  No 
15 55 M CHX Pyriform fossa Extra oral  III  2nd week  No 
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S.N
o 
Age  Sex  Group Location Extra/Intra 
oral 
Stage Onset of 
mucositis 
Ability to 
eat solid 
food 
1  48 M Soda  Tonsil Extra oral  IV  1st week  No 
2  71 M Soda  Tongue Intra oral  IV  2nd week  Yes 
3  49 F Soda  Posterior 
pharyngeal wall 
Extra oral  III  2nd week  Yes 
4  64 M Soda  Tongue Intra oral  III  1st week  No 
5  69 M Soda  Buccal mucosa Intra oral  IV  3rd week  Yes 
6  52 M Soda  Epiglottis Extra oral  IV  3rd week  Yes 
7  51 F Soda  Tongue Intra oral  III  1st week  No 
8  39 M Soda  Pyriform fossa Extra oral  IV  2nd week  No 
9  59 M Soda  Larynx Extra oral  IV  1st week  No 
10  58 M Soda  Tongue Intra oral  III  2nd week  Yes 
11  64 M Soda  Tonsil Extra oral  IV  1st week  No 
12  54 M Soda  Tongue Intra oral  IV  3rd week  Yes 
13  67 F Soda  Vocal cords Extra oral  III  1st week  No 
14  48 M Soda  Tongue Intra oral  IV  1st week  No 
15  61 M Soda  Buccal mucosa Intra oral  III  2nd week  Yes 
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S.No  Age  Sex  Group Location Extra/Intra 
oral 
Stage Onset of 
mucositis 
Ability to eat 
solid food 
1  56 M “m” M  Buccal mucosa Intra oral  III  1st week  Yes 
2  48 F “m” M  Oropharynx Extra oral  IV  3rd week  Yes 
3  70 M “m” M  Epiglottis Extra oral  III  1st week  No 
4  52 M “m” M  Tongue Intra oral  IV  2nd week  Yes 
5  59 M “m” M  Hypopharynx Extra oral  III  5th week  Yes 
6  62 M “m” M  Tongue Intra oral  III  2nd week  Yes 
7  49 M “m” M  Pyriform fossa Extra oral  IV  1st week  No 
8  58 F “m” M  Alveolus Intra oral  III  3rd week  Yes 
9  41 M “m” M  Tonsil Extra oral  IV  2nd week  No 
10  61 M “m” M  Tonsil Extra oral  IV  3rd week  Yes 
11  69 M “m” M  Pyriform fossa Extra oral  III  4th week  Yes 
12  71 F “m” M  Supraglottis Extra oral  IV  1st week  No 
13  53 M “m” M  Tonsil Extra oral  III  3rd week  Yes 
14  73 M “m” M  Buccal mucosa Intra oral  IV  2nd week  Yes 
15  43 F “m” M  Tongue Intra oral  III  1st week  No 
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S.No  Age  Sex  Group Location Extra/Intra 
oral 
Stage Onset of 
mucositis
Ability to 
eat solid 
food 
1  61 F Control  Posterior pharyngeal 
wall 
Extra oral  IV  1st week  No 
2  54 M Control  Tongue Intra oral  III  2nd week  Yes 
3  59 M Control  Buccal mucosa Intra oral  IV  1st week  No 
4  71 M Control  Pyriform fossa Extra oral  IV  1st week  No 
5  65 M Control  Tonsil Extra oral  IV  2nd week  Yes 
6  67 F Control  Tongue Intra oral  III  1st week  No 
7  43 M Control  Tonsil Extra oral  IV  1st week  No 
8  56 F Control  Epiglottis Extra oral  III  1st week  No 
9  60 M Control  Tongue Intra oral  III  1st week  No 
10  58 M Control  Maxillary antrum Extra oral  IV  2nd week  Yes 
11  49 M Control  Buccal mucosa Intra oral  IV  1st week  No 
12  58 F Control  Tongue Intra oral  III  1st week  No 
13  41 F Control  Buccal  mucosa Intra oral  III  1st week  No 
14  55 M Control  Alveolus Intra oral  III  1st week  No 
15  69 M Control  Supraglottis Extra oral  III  1st week  No 
 
